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THE ROLE OF ANXIETY IN THE DEVELOPMENT OF SUICIDAL 
THOUGHTS IN PREGNANT WOMEN WITH MOOD DISORDERS 
 
DEMETRA SCHERMERHORN 
ABSTRACT 
Background: Both mood and anxiety disorders are more prevalent in women than men 
with the onset typically occurring during adolescence or early childbearing years.  These 
disorders are particularly prevalent during pregnancy and the postpartum period. While 
depression during the perinatal period has received significant attention recently, anxiety 
has not received the same amount of attention.   
 
Methods: The current study was a secondary analysis of a prospective cohort study that 
followed 91 women with mood disorders through pregnancy and the postpartum period. 
Our objective was to determine if a correlation existed between anxiety and suicidality. 
We hypothesized that pregnant women with a history of a mood disorder and comorbid 
anxiety are more likely to be suicidal than those without comorbid anxiety. The presence 
of anxiety was determined using the anxiety subscale of the Edinburgh Postnatal 
Depression Scale, EPDS; a cut off score of six or greater was used to indicate significant 
anxiety. Suicidality was determined using three separate measures: question ten on the 
EPDS, question eighteen on the Inventory of Depressive Symptomatology, and question 
ten on the Montgomery-Asberg Depression Rating Scale.  
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Analysis: Chi square tests were used to compare the demographics of the anxious and 
non-anxious women based on both diagnosis of anxiety disorders and symptoms of 
anxiety. Z proportion tests were then used to compare the proportion women with anxiety 
versus those without anxiety who were suicidal. Lastly, binary logistic regression was 
used to determine if patients with anxiety were more likely to be suicidal.   
 
Results: Among the women in this study, 62 (68.1%) had a diagnosis of major depressive 
disorder and 29 (31.9%) had a diagnosis of bipolar disorder based on DSM-IV-TR 
diagnostic criteria. In addition, 45 (49.5%) had a lifetime history of an anxiety disorder. 
The prevalence of significant anxiety symptoms, as determined by the anxiety subscale 
on the EPDS, ranged from 9.1-37.5% depending on the time point. Suicidality prevalence 
also varied depending on both the time point and the scale used: 0-17.5% using the 
MADRS, 6.7-24.7% using the EPDS, and 2.4-14.7% using the IDS. Using a binary 
logistic regression, we determined that anxiety was a risk factor for suicidality at time T3 
(OR 2.106; 95% CI 1.274-3.481) and M1 (OR 2.057; 95% CI 1.179-3.586) on the 
MADRS and at T3 (OR1.758; 95% CI 1.219-2.535) on the EPDS.  
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INTRODUCTION 
Depression 
Depression is a serious disease that is characterized by feelings of sadness, 
hopelessness, guilt, and worthlessness. Typical symptoms of depression include loss of 
pleasure in everyday activities, fatigue, difficulty concentrating, weight loss or weight 
gain, and persistent feelings of sadness or emptiness (National Institute of Mental Health 
[NIMH], 2011). Depression is a common problem in today’s world; according to data 
from the US National Comorbidity Survey Replication and the associated Adolescent 
Supplement, the lifetime prevalence of Major Depressive Disorder (MDD) in people 
thirteen and older is 14.4% (Kessler, Petukhova, Sampson, Zaslavsky, & Wittchen, 
2012). Figure 1 shows the prevalence of depression in the US by age group and sex. 
Depression is the leading cause of disability for both men and women (World Health 
Organization [WHO], 2012). In recent years, depression has been termed a major public 
health problem in the United States (WHO, 2012). A major concern is the under 
diagnosis and treatment of depression.  
While depression is a serious disease, it is largely treatable (NIMH, n.d.-a). There 
are three types of treatment for depression: medication, psychotherapy, and brain 
stimulation therapies such as electroconvulsive therapy (ECT) and transcranial magnetic 
stimulation (TMS) (NIMH, 2011). A wide variety of antidepressants with various 
mechanisms of action are available including: selective serotonin reuptake inhibitors 
(SSRIs), tricylic antidepressants, monoamine oxidase inhibitors (MAOI), and serotonin 
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and norephineprine reuptake inhibitors (SNRI). SSRIs are the most commonly used 
antidepressants (Ellfolk & Malm, 2010). 
 
 
Figure 1. Prevalence of depression in the United States by age group and sex (CDC, 
2012). 
Depression in Women 
Depression is more prevalent in women than men (Kessler et al., 1994; Alonso et 
al., 2004; Kessler et al., 2012). As determined by the US National Comorbidity Survey 
Replication and the associated Adolescent Supplement, the lifetime prevalence of MDD 
is 18.1% for women and 10.7% for men (Kessler et al., 2012). It is hypothesized that a 
combination of biological differences (e.g. brain structure/function and hormones) and 
psychosocial factors are involved in the observed sex differences. (Furey, Khanna, 
Hoffman, & Drevets, 2010; NIMH, 2011). Studies have shown that one in five women 
will experience at least one episode of major depressive disorder (MDD) in their lifetime 
(Kessler, Zhao, Blazer, & Swartz, 1997; Noble, 2005; Marcus & Heringhausen, 2009).  
The gender difference in prevalence rates of depression first appears during adolescence, 
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a time of significant hormonal changes (Kessler et al., 1994; Weissman & Olfson, 1995; 
Hyde, Mezulis, & Abramson, 2008; Payne et al., 2008). As depicted in Figure 1, the 
gender differences in depression occur during the reproductive stage of a woman’s life. 
There are three specific time periods during a woman’s reproductive life with an 
increased risk of depression: prior to menstruation, postpartum, and perimenopause 
(Furey, Khanna, Hoffman, & Drevets, 2010; Payne et al., 2008). The premenstrual period 
occurs cyclically, while the postpartum period can occur several times during a woman’s 
life. Conversely, the perimenopausal period only occurs once, but may last for a few 
years. During each of these three time periods, there is a large drop in both estrogen and 
progesterone levels and as a result, it is hypothesized that hormonal changes are 
responsible for the increased risk of depression (Payne et al., 2008). While the incidence 
of depression is greater in women beginning in adolescence and continuing throughout 
their reproductive years, the incidence of depression in women drops to approximately 
the same as that observed in men following menopause (Jorm, 1987; Noble, 2005; Furey, 
Khanna, Hoffman, & Drevets, 2010).  
Diagnostic Criteria for Depression 
Major Depressive Disorder 
According to the Diagnostic and Statistical Manual of Mental Disorders IV-TR 
(DSM-IV-TR), a major depressive episode is diagnosed when at least five of the 
following symptoms (two of which must be symptom numbers one and two) are present 
almost every day during a two-week period and mark a change in function (4th ed., text 
rev.; DSM–IV–TR; American Psychiatric Association [APA], 2000):  
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1. Depressed for most of the day  
2. Significant decrease in interest or pleasure in all or almost all activities most of 
the day 
3. Significant weight loss in the absence of dieting or weight gain 
4. Insomnia or hypersomnia  
5. Psychomotor agitation or retardation  
6. Fatigue or loss of energy 
7. Feelings of worthlessness or excessive/inappropriate guilt 
8. Diminished ability to think, concentrate, or make decisions 
9. Recurrent thoughts about death, recurrent suicidal ideation, plan to commit 
suicide, or suicide attempt 
There are three criteria needed to diagnose major depressive disorder, MDD (APA, 
2000): 
1. The presence of a single major depressive episode 
2. The episode is not better defined by schizoaffective disorder and is not co-
occurring with schizophreniform disorder, delusional disorder, or psychotic 
disorder not otherwise specified 
3. The absence of manic episodes 
 
 
The DSM-IV-TR does not recognize postpartum depression as a separate disorder, rather 
it is a “specifier” under major depressive disorder (APA, 2000). For a patient to be 
diagnosed with “postpartum depression” they must meet the criteria for both major 
depressive disorder and the postpartum depression specifier (APA, 2000). The specifier 
of postpartum depression applies only if the onset of depression is within four weeks of 
delivery.  
Depressive Disorder Not Otherwise Specified 
 A diagnosis of depressive disorder not otherwise specified is given when the 
depressive features do not meet criteria for one of the depressive disorders, such as MDD 
(APA, 2000). An example of depressive disorder NOS is minor depressive disorder 
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which is given when a patient exhibits depressive symptoms for at least two weeks but 
has fewer than the five symptoms needed to diagnose MDD (APA, 2000).  
Bipolar Disorder 
 Bipolar disorder (BPAD) is a mood disorder, which causes extreme mood swings 
from high, mania or hypomania, to low, depression (Mayo Clinic, 2015).  According to 
the US National Comorbidity Survey Replication, the lifetime prevalence of any bipolar 
disorder in ages 13 and older is 2.5%: 2.7% in women and 2.2% in men (Kessler et al., 
2012).  
Diagnostic Criteria 
Bipolar I Disorder  
 Bipolar I Disorder (BP I) is characterized by mania or daily rapid cycling 
episodes of mania and depression (APA, 2000). The following criteria are used to 
diagnose BP I (APA, 2000): 
1. The presence of one of more manic or mixed episodes 
Manic episode: 
a. Persistent elevated, expansive, or irritable mood for at least one week 
(unless hospitalization is required) 
b. At least three of the following symptoms are present during mood 
disturbance (four if mood is irritable): inflated self-esteem or 
grandiosity, decreased need for sleep, increased talkativeness, flight of 
ideas or racing thoughts, distractibility, increase in goal-directed 
activity or psychomotor agitation, increase in risk behavior 
c. Symptoms do not meet criteria for a mixed episode 
d. Level of severity is sufficient to cause social or occupation impairment, 
hospitalization, or psychotic features 
e. Symptoms are not due to a substance or medical condition 
 Mixed Episode  
a. Criteria for both manic and major depressive episode are met 
(excluding duration) almost every day for at least one week 
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b. Level of severity is sufficient to cause social or occupation impairment, 
hospitalization, or psychotic features 
c. Symptoms are not due to a substance or medical condition 
2. The symptoms cause social or occupational distress or impairment 
3. The symptoms are not better accounted for by Schizoaffective Disorder, and are 
not superimposed on Schizpophrenia, Schizophreniform Disorder, Delusional 
Disorder, or Psychotic Disorder Not Otherwise Specified 
Bipolar II Disorder  
 Bipolar II Disorder (BP II) is characterized by recurrent depression accompanied 
by hypomanic episodes, a milder state of mania in which symptoms are not severe 
enough to cause marked impairment, but are observable by others. The following criteria 
are needed to diagnose BP II (APA, 2000):  
1. Presence (or history) of one or more major depressive episode 
2. Presence (or history) of at least one hypomanic episode 
Hypomanic episode:  
a. A distinct period of persistently elevated, expansive, or irritable mood, 
lasting throughout at least 4 days, that is clearly different from the 
usual non depressed mood 
b. During the period of mood disturbance, three (or more) of the 
following symptoms have persisted (four if the mood is only irritable) 
and have been present to a significant degree: inflated self-esteem or 
grandiosity, decreased need for sleep, increased talkativeness, flight of 
ideas or racing thoughts, distractibility, increase in goal-directed 
activity or psychomotor agitation, increase in risk behavior 
c. The episode is associated with an unequivocal change in functioning 
that is uncharacteristic of the person when not symptomatic.  
d. The disturbance in mood and the change in functioning are observable 
by others 
e. The episode is not severe enough to cause marked impairment in 
social or occupational functioning, or to necessitate hospitalization, 
and there are no psychotic features 
f. The symptoms are not due to the direct physiological effects of 
a substance or a general medical condition  
3. There has never been a manic episode or a mixed episode  
4. The mood symptoms in criteria 1 and 2 are not better accounted for by 
Schizoaffective Disorder, and are not superimposed on Schizpophrenia, 
Schizophreniform Disorder, Delusional Disorder, or Psychotic Disorder Not 
Otherwise Specified 
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5. The symptoms cause clinically significant distress or impairment in social, 
occupational, or other important areas of functioning  
 
Bipolar Disorder Not Otherwise Specified  
 Bipolar disorder not otherwise specified (BP NOS) is given when bipolar features 
are present but do not fit into the category of BP I or BP II (APA, 2000). The following 
are examples of when a diagnosis of BP NOS may be given (APA, 2000):  
1. Rapid alteration between manic and depressive symptoms that meet symptom 
threshold criteria but not minimal duration criteria  
2. Recurrent hypomanic episodes without intercurrent depressive symptoms.  
3. A manic or mixed episode superimposed on delusional disorder, residual 
schizophrenia or psychotic disorder NOS  
4. Hypomanic episodes along with chronic depressive symptoms, that are too 
infrequent to qualify for a diagnosis of cyclothymic disorder 
5. Situations where bipolar disorder is present but the clinician is unable to determine 
whether it is primary or secondary to a general medical condition or substance 
abuse 
 
Perinatal Depression  
Perinatal depression is defined as depression that occurs during pregnancy or after 
giving birth. However, the time period after giving birth that is defined as “postpartum” 
varies widely in the literature; for example, Murphy-Eberenz et al. defined perinatal 
major depression as “any episode during pregnancy or the month after childbirth” while 
Gavin et al. stated that perinatal depression “encompasses major and minor depressive 
episodes that occur either during pregnancy or within the first 12 months after delivery” 
(Murphy-Eberenz et al., 2006; Gavin et al., 2005).  Depression that occurs during 
pregnancy, but before the delivery is referred to as antenatal or antepartum depression 
and depression that occurs after the delivery is referred to as postpartum or postnatal 
depression. However, the term “postpartum depression” or “PPD” is used differently 
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throughout the literature. In some studies, this term refers to depression that begins 
immediately after delivery (begins within four weeks of delivery), in others it refers to 
depression that begins during pregnancy and continues into the postpartum period, and in 
yet others it refers to depression that starts after delivery but not necessarily during the 
first four weeks. According to the DSM-IV-TR, postpartum depression is depression with 
onset in the first four weeks following delivery. While it is debated whether the definition 
of PPD should be expanded to include depression that begins later in the postpartum 
period, research supports the use of the current definition. Studies show that there is a 
genetic basis in families for depressive episodes beginning within four weeks after the 
delivery, but not for episodes beginning after that (Payne et al., 2008; Forty et al., 2006; 
Murphy-Eberenz et al., 2006).  
Prevalence 
While many studies have attempted to determine the prevalence of perinatal 
depression, the estimates vary widely depending on the criteria that were used to identify 
depression. It is estimated that between 10% and 16% of pregnant women meet the 
formal criteria for MDD and up to 20% experience depressive symptoms (Marcus & 
Heringhausen, 2009; Gotlib et al., 1989; Burt & Stein, 2002). The ranges in estimates of 
postpartum depression vary from 3-13% (Gavin et al., 2005; O’Hara & Swain, 1996; 
Campbell & Cohn, 1991). Some researchers determine the prevalence of any depression, 
including both minor and major depression, while others only look at major depression. 
Dietz et al. conducted a retrospective cohort study to determine the prevalence of 
diagnosed depression before, during, and after pregnancy (Dietz et al., 2007). Before 
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pregnancy was defined as 39 weeks prior to pregnancy and after pregnancy was defined 
as 39 weeks after pregnancy. Women were classified as being depressed if they had one 
of a few specific ICD-9-CM diagnoses, including major depressive disorder, dysthymic 
disorder, adjustment disorder with depressed mood, atypical depressive disorder, and 
depressive disorder not otherwise specified. The prevalence of depression at different 
time points was as follows: 8.7% before pregnancy, 6.9% during pregnancy, and 10.4% 
after pregnancy. Overall, 15.4% of women were depressed during at least one of the 
phases (Dietz et al., 2007). Gavin et al. conducted a systematic review of studies to 
determine the prevalence and incidence of perinatal depression (Gavin et al., 2005). They 
found that up to 19.2% of women have depressive episodes, either major or minor 
depression, during the first three months postpartum while 7.1% have a major depressive 
episode during that time period. Table 1 shows the prevalence of depression at various 
time points as determined by Gavin et al. For example, the prevalence of major and 
minor depression at the 3
rd
 trimester and one month postpartum were 8.5%, and 9.7%, 
respectively. However, the prevalence of major depression alone at these time points 
were 3.1% in the third trimester and 3.8% at one month postpartum (Gavin et al., 2005). 
With the varying rates of perinatal depression in the literature, it is clear that perinatal 
depression a significant problem that warrants further research.  
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Table 1. Estimates of the prevalence of major and minor Depression (adapted from 
Gavin et al., 2007) 
Point in Time Estimate (%) 95% Confidence 
Interval (%) 
Number of 
Studies 
Included in 
Estimate 
1
st
 trimester 11.0 7.6-15.8 2 
2
nd
 trimester 8.5 6.6-10.9 4 
3
rd
 trimester 8.5 6.5-11.0 5 
1 week PP 5.5 1.8-12.4 1 
1 month PP 9.7 7.7-12.3 6 
2 months PP 10.6 8.7-13.0 5 
3 months PP 12.9 10.6-15.8 4 
4 months PP 10.6 7.3-14.7 1 
5 months PP 10.6 7.3-14.7 1 
6 months PP 9.9 6.4-14.5 1 
7 months PP 10.6 7.1-15.6 2 
8 months PP 6.5 4.0-9.9 1 
12 months PP 6.5 2.7-12.9 1 
 
Risk Factors 
 Women with a history of MDD or (BPAD) are at increased risk for postpartum 
depression (Dean, Williams, & Brockington, 1989; Payne et al., 2007; Viguera et al., 
2011). In addition, a previous episode of PPD is a risk factor not only for future episodes 
of PPD but also for future episodes of MDD (Wisner et al., 2001; Wisner et al. 2004; 
Robertson, Grace, Wallington, & Stewart, 2004; Frank, Kupfer, Jacob, Blumenthal, & 
Jarrett, 1987). For example, Wisner et al. found that after one episode of PPD, the risk of 
a future episode of PPD was 25% (Wisner et al., 2001; Davidson & Robertson, 1985). 
Women with a family history of PPD are also at increased risk for PPD (Murphy-Eberenz 
et al., 2006; Payne et al., 2008; Kimmel et al., 2014). Kimmel et al. (2014) determined 
that the percentage of women that developed PPD who had a family history of PPD 
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(55.3%) was statistically larger (p<0.05) than the percentage of women that did not 
develop PPD who had a family history of PPD (11.8%).  According to Payne et al. 
(2008), the odds ratio for postpartum mood symptoms, excluding mania, with a family 
history of postpartum mood symptoms was 2.71.  
 Many studies have shown that anxiety is a risk factor for perinatal depression. 
Kirpinar, Gozum, and Pasinlioglu (2010) conducted a prospective study in eastern 
Turkey to examine the prevalence and risk factors of PPD. They found that psychiatric 
problems during pregnancy, anxiety during pregnancy, lack of health insurance, and a 
poor marital relationship in the immediate postpartum period were all risk factors for 
PPD (Kirpinar, Gozum, & Pasinlioglu, 2010). Another prospective study by Verreault et 
al. (2014) examined the rates and risk factors of depression during pregnancy (third 
trimester) and during the postpartum period (3 months postpartum). Depression was 
diagnosed based on score of ten or greater on the Edinburgh Postnatal Depression Scale 
(EPDS) (Cox, Holden, & Sagovsky, 1987). Of the 364 participants at the third trimester, 
28.3% reported depression and of the 226 participants at three months postpartum, 16.4% 
reported depression (Verreault et al., 2014). They found the following to be risk factors 
for depression during pregnancy: history of emotional problems (depression or anxiety), 
history of sexual abuse, comorbid anxiety, high anxiety sensitivity, and previous stressful 
life events (Verreault et al., 2014).  Risk factors for depression during the postpartum 
period included: sub-threshold depressive symptoms during pregnancy, history of 
depression or anxiety, low social support during pregnancy, and a more difficult delivery 
than expected (Verreault et al., 2014).  Milgrom et al. (2008) examined antenatal risk 
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factors for PPD using prospective a cohort design in Australia. PPD was determined 
using a score of greater than twelve on the EPDS (Milgrom et al., 2008). They 
determined that a history of depression, antenatal anxiety, antenatal depression, and low 
partner support were risk factors for PPD (Milgrom et al., 2008). Similarly, Grant, 
McMahon, Austin (2008) used a prospective cohort design in Australia to study maternal 
anxiety. They found that anxiety during pregnancy, based on diagnosis and the trait 
component of the State-Trait Anxiety Inventory (Spielberger, Gorsuch, & Lushene, 1970) 
predicted postpartum anxiety and mood disorders (Grant et al., 2008).  
Consequences 
Untreated depression during pregnancy can have negative effects for both the 
mother and the infant. Women who are depressed during pregnancy are more likely to 
engage in unhealthy behaviors and as a result, maternal depression has been associated 
with increased use of cigarettes, alcohol, and substance abuse, overall poor health, 
decreased gestational weight gain, and poor nutrition (Zuckerman, Amaro, Bauchner, & 
Cabral, 1989; Orr, Blazer, James, & Reiter, 2007; Marcus and Heringhausen, 2009; 
Yonkers et al., 2009). Depression during pregnancy can also lead to adverse birth 
outcomes such as premature delivery, lower APGAR scores, lower birth weight, and 
preeclampsia (Marcus and Heringhausen, 2009).  APGAR scores asses the baby’s 
breathing, heart rate, muscle tone, reflexes, and skin color at one and five minutes after 
birth (National Library of Medicine, 2015). Research has shown that infants who were 
exposed to maternal depression in utero have elevated levels of cortisol and 
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catecholamine at birth and as a result, they cry more and are harder to console (ACOG, 
2008; Marcus and Heringhausen, 2009).  
Postpartum depression can also have long-term effects on the infant such as 
behavioral issues, impaired emotional and linguistic development, delayed cognitive 
skills, and increased risk of psychiatric problems later in life (Coghill, Caplan, Alexandra, 
Robson, & Kuman, 1986; Murray & Stein, 1989; Brand & Brennan, 2009; Marcus and 
Heringhausen, 2009; Murray et al., 2011). Other consequences of PPD include increased 
visits to the emergency department and missed pediatric appointments (Flynn, Davis, 
Marcus, Cunningham, & Blow, 2004; Gavin et al., 2005). Lastly, PPD can be potentially 
fatal, resulting in suicide or infanticide (Spinelli, 2004; Lindahl, Pearson, & Colpe, 2005).  
 
Anxiety 
 According to the American Psychological Association, anxiety is “an emotion 
characterized by feelings of tension, worried thoughts and physical changes” (American 
Psychological Association, 2015). Anxiety is a normal response to stress, however, when 
anxiety lasts longer, is recurrent, causes impairment, and is extremely distressing it is 
considered pathological anxiety (Starcevic, 2005; NIMH, n.d.-b). There are many 
different anxiety disorders with different symptoms, however they all revolve around 
excessive, irrational fear and dread (Rowney, Hermida, & Malone, 2014). According to 
the DSM-IV-TR, the following are classified as anxiety disorders: generalized anxiety 
disorder (GAD), panic disorder, agoraphobia without history of panic disorder, specific 
phobia, social phobia, obsessive-compulsive disorder (OCD), posttraumatic stress 
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disorder (PTSD), acute stress disorder (ASD), substance induced anxiety disorder, and 
anxiety secondary to a medical condition (APA, 2000).  
 According to the US National Comorbidity Survey Replication, the lifetime 
prevalence of any anxiety disorder in ages 13 and older is 31.6%: 37.3% for women and 
25.6% for men (Kessler et al., 2012). For each specific disorder the total lifetime 
prevalence are as follows: 3.8% for panic disorder, 4.3% for GAD, 10.7% for social 
anxiety, and 2.3% for OCD (Kessler et al., 2012). 
Diagnostic Criteria for Anxiety  
Generalized Anxiety Disorder 
According to the Diagnostic and Statistical Manual of Mental Disorders IV-TR 
(DSM-IV-TR), there are six criteria needed to diagnose Generalized Anxiety Disorder 
(APA, 2000).  
1. Excessive anxiety and worry (apprehensive expectation), occurring more 
days that not for at least 6 months, about a number of events or activities 
(such as work or school or performance) 
2. The person finds it difficult to control the worry 
3. The anxiety and worry are associated with three (or more) of the following 
six symptoms (with at least some symptoms present for more days than not 
for the past 6 months) 
a. Restlessness or feeling keyed up or on edge 
b. Being easily fatigued 
c. Difficulty concentrating or mind going blank 
d. Irritability 
e. Muscle tension 
f. Sleep disturbance (difficulty falling or staying asleep, or restless 
unsatisfying sleep) 
4. The focus of the anxiety and worry is not confined to features of an Axis I 
disorder, being embarrassed in public, being contaminated, being away 
from home or close relatives, gaining weight, having multiple physical 
complaints, or having a serious illness, and the anxiety and worry do not 
occur exclusively during Posttraumatic Stress Disorder 
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5. The anxiety, worry, or physical symptoms cause clinically significant 
distress or impairment in social, occupational, or other important areas of 
functioning  
6. The disturbance is not due to the direct physiological effects of a substance 
or a general medical condition and does not occur exclusively during a 
Mood Disorder, a Psychotic Disorder, or a Pervasive Developmental 
Disorder (APA, 2000) 
 
Obsessive-Compulsive Disorder 
There are four criteria needed to diagnose Obsessive-Compulsive Disorder 
according to the DSM-IV-TR (APA, 2000).  
1. Either obsessions and/or compulsions are present 
Definition of obsessions: 
a. Recurrent and persistent thoughts, impulses, or images that are 
experienced as intrusive and inappropriate, causing anxiety or distress 
b. The thoughts, impulses, or images are not simply excessive worries 
about real-life problems 
c. The person attempts to ignore or suppress such thoughts, impulses, or 
images or to neutralize them with some other thought or action 
d. The person recognizes that the obsessional thoughts, impulses, or 
images are a product of his or her own mind 
Definition of compulsions: 
a. Repetitive behaviors or mental acts that the person feels driven to 
perform in response to an obsession or according to rules that must 
be applied rigidly 
b. The behaviors or mental acts are aimed at preventing or reducing 
distress or preventing some dreaded event or situation 
c. These behaviors or mental acts either are not connected in a realistic 
way with what they are designed to neutralize or prevent, or they are 
clearly excessive 
2. At some point during the course of the disorder, the person has recognized 
that the obsessions or compulsions are excessive or unreasonable 
3. The obsessions or compulsions cause marked distress, take up more than 1 
hour a day, or significantly interfere with the person's normal routine, 
occupation, or usual social activities 
4. If another Axis I disorder, substance use, or general medical condition is 
present, the content of the obsessions or compulsions is not restricted to it 
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Panic Disorder 
 The following characteristics are needed to diagnose panic disorder according to 
the DSM-IV-TR (APA, 2000).  
1. Recurrent unexpected panic attacks which are periods of intense fear or 
discomfort, developing abruptly and peaking within 10 minutes and contain at 
least four of the following symptoms:  
a. Chest pain or discomfort, chills or hot flushes, derealization or 
depersonalization, fear of losing control, feeling dizzy, unsteady, 
lightheaded, or faint, feeling of choking, nausea or abdominal distress, 
palpitations or tachycardia, paresthesias, sensations or shortness of 
breath or smothering, sense of impending doom, sweating, trembling 
or shaking 
2. At least of the following has been followed by a minimum of one month of 
the following: 
a. Persistent concern about having additional panic attacks 
b. Worry about the implications of the attacks or its consequences 
c. A significant change in behavior related to the attacks 
3. Presence or absence of agoraphobia 
4. The panic attacks are not due to the direct physiologic effects of a substance 
(e.g., a drug of abuse, a medication) or a general medical condition (e.g., 
hyperthyroidism) 
5. The panic attacks are not better accounted for by another mental disorder  
 
Social Anxiety 
 According to the DSM-IV-TR, social anxiety is diagnosed based on the following 
criteria (APA, 2000):  
1. A fear of one or more social or performance situations in which the person is 
exposed to unfamiliar people or to possible scrutiny by others and feels he or 
she will act in an embarrassing manner 
2. Exposure to the feared social situation provokes anxiety, which can take the 
form of a panic attack 
3. The person recognizes that the fear is excessive or unreasonable. 
4. The feared social or performance situations are avoided or are endured with 
intense distress 
5. The avoidance, anxious anticipation, or distress in the feared situation 
interferes significantly with the person's normal routine, occupational 
functioning, or social activities or relationships 
6. The condition is not better accounted for by another mental disorder, 
substance use, or general medical condition 
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7. If a general medical condition or another mental disorder is present, the fear is 
unrelated to it 
 
Anxiety Disorder Not Otherwise Specified 
 According to the DSM-IV-TR, patients that have significant anxiety symptoms 
who do not meet the criteria for any specific anxiety disorder, adjustment disorder with 
anxiety, or mixed anxiety and depressed mood are given the diagnosis of anxiety disorder 
not otherwise specified (APA, 2000).  
 
Perinatal Anxiety 
Most of the research regarding psychiatric disorders during the perinatal period 
has been on depression with less focus on anxiety. However, studies have shown that 
anxiety is also a significant problem during the perinatal period that should be addressed. 
According to Shear and Oommen, the postpartum period is a period of increased risk for 
the onset or progression of anxiety disorders (Shear & Oommen, 1994).  A challenge to 
studying anxiety is the amount of overlap between anxiety and depression. Many patients 
diagnosed with MDD experience accompanying anxious features characterized by 
symptoms of anxiety and arousal of the sympathetic nervous system (McClintock et al., 
2011). Despite this, anxiety is not specifically included as a symptom in the diagnostic 
criteria for Major Depressive Disorder in the DSM-IV-TR; although psychomotor 
agitation, non-goal oriented motor activity associated with mental distress, is included as 
a symptom of MDD in the DSM-IV-TR (Day, 1999). Furthermore, “depression with 
anxious features” is not listed as a disorder in the DSM-IV-TR, however, it has been 
defined in the literature as “either MDD with high levels of anxiety symptoms or the 
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concurrent (not lifetime) presence of depression and anxiety” (McClintock et al., 2011; 
Fava et al., 2004). Interestingly, Stuart, Couser, Schilder, O’Hara, and Gorman (1998) list 
“intense anxiety” as one of the symptoms of postpartum depression, in addition to 
psychomotor agitation, depressed mood, lack of libido, appetite and sleep disturbances, 
and excessive fatigue. Hendrick, Altshuler, Strouse, and Grosser (2000) found that 
anxiety symptoms were more common in women with PPD than in women with 
depression who were not postpartum; only 16% of the non-postpartum depressed women 
were anxious compared to 73.3% of the women with PPD who were anxious. The 
combination of depressive and anxiety symptoms seen in PPD has led researchers to 
wonder if PPD is a distinct type of depression separate from major depressive disorder. 
Pitt labeled postpartum depression as “atypical depression” (Pitt, 1968). 
There is also a high level of comorbidity between MDD and anxiety disorders. 
Kessler et al. examined a community sample and found the rate of comorbid lifetime 
anxiety and MDD (DSM-III-R) to be between 60-65% (Kessler et al., 1996). 
Interestingly, they found that the majority of cases of lifetime MDD were secondary to 
other disorders, with anxiety disorders being the most common primary disorder (Kessler 
et al., 1996). In a replicate study, Kessler et al. found the comorbidity of MDD (DSM-IV) 
and anxiety disorders to be 59.2% (Kessler et al., 2003). Wisner et al. conducted a large-
scale screening for postpartum depression between 4 and 6 weeks after delivery (Wisner 
et al., 2013). Of the participants diagnosed with a primary depressive episode, 66.1% had 
comorbid anxiety disorders (Wisner et al., 2013). The most common comorbid anxiety 
disorder was Generalized Anxiety Disorder (GAD) (Wisner et al., 2013). Both Enatescu 
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et al. and Stuart et al. observed a correlation between the levels of anxiety and depression 
in their studies (Enatescu et al., 2014; Stuart et al., 1998). 
Not only are anxiety and depression often comorbid, but studies also show 
anxiety is a risk factor for depression. Matthey, Barnett, Howie, and Kavanagh (2003) 
conducted a prospective cohort study examining depression and anxiety in first-time 
parents and found high levels of anxiety among women during the postpartum period. 
They determined that a previous history of an anxiety disorder was a greater risk factor 
for postpartum depression or anxiety than a history of depression; 65.6% of the women 
who reported a history of anxiety disorders developed either postpartum anxiety or 
depression, compared to 29.4% of women who only had a history of depression (Matthey 
et al., 2003). Similarly, Kirpinar et al. discovered that prenatal anxiety was a risk factor 
for postpartum depression (Kirpinar et al., 2010). 
 
Prevalence 
Goodman, Chenausky, and Freeman (2014) conducted a literature review on the 
prevalence of anxiety during the perinatal period; they found that the prevalence rates for 
any anxiety disorder ranged from 4.4% to 39%. In a study by Matthey et al. (2003), 
patients were recruited during pregnancy, divided into two samples, and interviewed 
between six and eight weeks postpartum. Of the two samples, 5.6% and 2.1% of the 
mothers experienced only depression (either major or minor) at 6-8 weeks postpartum. In 
addition, 4.2% and 2.1% of women experienced both depression and anxiety while 16.2 
and 10.4% experienced only anxiety. In total, 25.9% and 15.1% experienced depression 
and/or anxiety at 6-8 weeks postpartum. The authors make the point that not all women 
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with anxiety during the postpartum period are depressed and therefore by not including 
anxiety in research, we are not gathering a true sense of the psychological disturbances 
that may occur following birth. One limitation of this study is that the participants 
underwent psychosocial prevention programs as part of the study, potentially impacting 
the rates of anxiety and depression (Matthey et al., 2003).  
Stuart et al. (1998) conducted a prospective cohort study to examine the rates of 
postpartum anxiety and the relationship between anxiety and depression. They used self-
report scales to examine the rates of anxiety and depression. The Beck Anxiety 
Inventory, BAI, (Beck, Epstein, Brown, & Steer, 1988), which examines the severity of 
anxiety symptoms over the past week, was used as the primary measure for anxiety 
(Stuart et al., 1998). In this study, the point prevalence of anxiety was 8.7% and 16.8% at 
14 weeks and 30 weeks postpartum, respectively. The incidence of anxiety from 14 to 30 
weeks postpartum was 10.28% (Stuart et al., 1998).  
Consequences 
Anxiety and stress during the antenatal period have been associated with many of 
the same adverse effects as depression including low infant birth weight, preterm labor, 
and elevated fetal heart rate (Schofield, 2014; Field et al., 2003; Dayan et al., 2002). Van 
den Bergh, Mulder, Mennes, and Glover (2005) conducted a review of fourteen studies 
that showed a direct link between maternal anxiety and stress and the neurodevelopment 
of the fetus/child. Overall, the studies showed that anxiety and stress during pregnancy 
lead to behavioral, emotional, and cognitive problems for the child (Van den Bergh et al., 
2005; O’Connor, Heron, Golding, Beveridge, & Glover, 2002). For example, infants of 
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anxious mothers were shown to have poorer language abilities (Laplante et al., 2004) and 
more sleeping, feeding, and activity problems (Van den Bergh, 1990). Three studies 
found that the infants had lower scores on the Bayley Scales of Infant Development at 
two 8 and 24 months (Huizink, de Medina, Mulder, Visser, & Buitelaar, 2002; Brouwers, 
van Baar, & Pop, 2001; Laplante et al., 2004), while a fourth study found that the scores 
were not worse at 7 months (Vaughn, Bradley, Joffe, Seifer, & Barglow, 1987).   
Multiple studies showed that pre-school children and older children had poorer attention, 
hyperactivity, and behavioral problems (Van den Bergh et al., 2005; O’Connor et al., 
2002; Van den Bergh & Macoen, 2004). Although some discrepancies existed among the 
studies, overall the results showed that anxiety and stress during pregnancy lead to 
adverse effects in children (Van den Bergh et al., 2005). 
 
Suicidality 
 Out of the many negative consequences of psychiatric problems during the 
perinatal period, the most devastating, and permanent is suicide. Suicidality is defined as 
“suicide deaths, intentional self-harm, with or without intent to die, and thoughts of death 
and self-harm” (Mauri, Oppo, Borri, & Banti, 2012). In 2010, suicide was the 10th 
leading cause of death in the general population and accounted for 1.6% of all deaths 
(Heron, 2013). It was the second leading cause of death for those aged 10-24, accounting 
for 15% of deaths and the fourth leading cause for those aged 25-44 (11% of deaths) 
(Heron, 2013). While suicide is common, suicidal ideation (SI) is even more common. 
According to Crosby, Han, Ortega, Parks, and Gfroerer, from 2008-2009 3.7% of adults 
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in the US had suicidal thoughts, 1% made suicide plans, and 0.5% made a suicide attempt 
(Crosby et al., 2011).   
Studies have shown that suicidal ideation is more common in women than men, 
and women are more likely to attempt suicide (Crosby et al., 2011; Newport, Levey, 
Pennell, Ragan, & Stowe, 2007).  Although interestingly in 2010 suicide was not in the 
top ten leading causes of death for women, while it was the seventh leading cause of 
death in men. Lindahl, Pearson, and Colpe (2005) conducted a literature review of studies 
that examined suicidality in pregnancy and the postpartum period including only those 
studies with defined community or clinic samples. The review included twenty-seven 
papers, twelve of which took place in the US (Lindahl et al., 2005). Overall, the literature 
showed that suicide rates are lower in pregnant and postpartum women than in the 
general female population (Lindahl et al., 2005). However, women who committed 
suicide during pregnancy or postpartum were more likely to use a violent method of 
death compared with the general population (Lindahl et al., 2005). The authors also 
looked at the subset of studies that administered the EPDS to postpartum women. They 
found that the percent of women who endorsed some thoughts of self-harm, based on 
EPDS number 10, ranged from 4% in Finland to 15.4% in India (Lindahl et al., 2005; 
Patel, Rodrigues, & DeSouza, 2002; Louma et al., 2001). In the two US studies, 5.3% 
and 8.75% of postpartum women endorsed some thoughts of self-harm (Georgiopoulus et 
al., 1999; Yonkers et al., 2001; Lindahl et al., 2005). 
 Newport et al. recruited pregnant women from a women’s mental health clinic 
and a women’s epilepsy program for a prospective observational study to examine 
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suicidality in pregnant women (Newport et al., 2007). In this study, item nine on the Beck 
Depression Inventory, BDI, (Beck et al., 1961) and item three on the Hamilton Rating 
Scale for Depression, HRSD (Hamilton, 1960) were used to measure suicidal ideation 
(Newport et al., 2007). The two measures yielded different results with 27.8% of the 
women endorsing SI on the BDI versus 16.7% on the HRSD. Using a multivariate 
logistics regression, the authors found that unplanned pregnancy (OR=2.97), lifetime 
diagnosis of anxiety disorder (OR-4.17), and current major depression (OR=4.12) were 
significant predictors of suicidal ideation (Newport et al., 2007). These rates are higher 
because they draw from a specific population of women, those seen at a mental health 
clinic, as opposed to the general population.  
Anxiety and Suicidality 
 Some studies have shown that anxiety is associated with elevated rates of 
suicidality (Sareen et al., 2005; Newport et al., 2007; Farias et al., 2013; Schofield, 
Battle, Howard, 2014). Sareen et al. conducted a large population-based prospective 
cohort study in the Netherlands to determine if anxiety disorders were a risk factor for 
suicidality (Sareen et al., 2005). Using a longitudinal analysis they found that the 
presence of an anxiety disorder was significantly associated with suicidal ideation (aOR 
2.32; 95% CI 1.31-4.11) and suicide attempts (aOR 3.64; 95% CI 1.70-7.83). A cross-
sectional analysis also showed that anxiety disorders were a risk factor suicidal ideation 
(aOR 2.29; 95% CI 1.85-2.82) and suicide attempts (aOR 2.84; 95% CI 1.70-3.62) 
(Sareen et al., 2005). In addition, the presence of an anxiety disorder with a comorbid 
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mood disorder increased the risk of suicide attempts as compared to a mood disorder 
alone (Sareen et al., 2005).  
Farias et al. (2013) used a cross-sectional analysis to determine the prevalence of 
psychiatric disorders and current suicide risk (CSR) in Brazilian women during their first 
trimester of pregnancy. CSR was defined as “thoughts and suicide attempts” and was 
assessed using the suicidality module in the Mini-International Neuropsychiatric 
Interview, M.I.N.I (Farias et al., 2013). The M.I.N.I is a structured psychiatric interview 
used by clinicians to obtain DSM-IV and ICD-10 psychiatric diagnoses (Sheehan et al., 
1998). They found that women with depression were 3.83 times more likely to have 
suicidal ideation, while women with anxiety were 10.05 times more likely to have 
suicidal ideation. Overall, generalized anxiety disorder, major depressive disorder, and 
higher parity were associated with CSR in women during their first trimester of 
pregnancy (Farias et al., 2013). 
 While research has shown that anxiety during the perinatal period is a serious 
issue with severe and potentially fatal consequences, there has yet to be a shift in focus 
from depression alone to depression and anxiety. Unlike depression, anxiety is not 
commonly screened for during the perinatal period. Research shows that depression with 
comorbid anxiety is particularly dangerous as it has poorer outcomes and is harder to 
treat than depression alone (Hendrick et al., 2000; Fava et al., 1997; Emmanual, 
Simmonds, & Tyrer, 1998). A few studies have even found an increased risk of 
suicidality in patients with anxiety (Cougle, Keough, Riccardi, & Sachs-Ericsson, 2009; 
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Schofield et al., 2014). We hoped to learn more about the relationship between anxiety 
and suicidality during the perinatal period.  
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SPECIFIC AIMS 
We sought to determine if pregnant women with comorbid anxiety and mood 
disorders have increased suicidality in comparison to pregnant women with mood 
disorders alone. To accomplish this, we undertook a secondary analysis of a data set that 
was originally collected with the objective of determining the clinical, genetic, and 
environmental risk factors for PPD in pregnant women with mood disorders. The original 
study prospectively studied pregnant women with mood disorders throughout pregnancy 
and up to three months postpartum. Our specific aim was the following: 
 Examine the impact of anxiety on the development of suicidal thoughts during the 
perinatal period in women with mood disorders. 
We hypothesized that pregnant women with a history of a mood disorder and comorbid 
anxiety are more likely to be suicidal than those without comorbid anxiety. 
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METHODS 
This study is a secondary analysis of the study titled “A Prospective Study of 
Postpartum Mood Episodes in Women with Affective Disorders”. The parent study was a 
prospective cohort study, which followed women with mood disorders through 
pregnancy and the postpartum period in order to identify risk factors of PPD. To date 
there are two publications regarding the parent study (Kimmel et al, 2014; Guintivano, 
Arad, Gould, Payne, & Kaminsky, 2013).   
 
Recruitment 
In the initial study, we planned to recruit approximately 120 women ages 18 and 
older that were pregnant and had a history of a mood disorder (including MDD, BP I, BP 
II, or BPNOS) between 2007 and 2012. While we hoped to recruit women as early in 
their pregnancy as possible, women in any trimester were accepted into the study. 
Women were recruited directly from the Johns Hopkins Women’s Mood Disorder Center 
(WMDC) and from the “Healthy Start” program as well as by referral from other 
psychiatrists and obstetricians, word of mouth, and through local advertisements and 
flyers. In addition, two patients were recruited at a second site, University of North 
Carolina at Chapel Hill (UNC). Current patients at the WMDC were approached by a 
physician and asked if they were interested in learning about the current research studies. 
The patients then signed an IRB approved form entitled Authorization to Contact You 
About Future Research Studies indicating yes or no whether they wanted to be contacted 
about research. If they indicated yes, a research assistant called them to schedule a 
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screening visit. If they indicated no, they were not contacted. Local advertisements were 
placed in Baltimore Magazine, Baltimore’s Child, City Paper, Columbia Flier, Craigslist, 
Dundalk Eagle, and Women’s Journal. Women who called in response to local 
advertisements completed a phone screening and if eligible, were then scheduled for a 
screening visit.  
 
Inclusion and Exclusion Criteria 
Table 2 shows the inclusion and exclusion criteria for the parent study. In order to 
be eligible for the study, women had to be pregnant, at least 18 years old, have a history 
of a mood disorder, and if applicable, be in treatment for management of the current 
illness. Diagnosis of lifetime history and/or current mood disorder was made using the 
Structured Clinical Interview for DSM-IV-TR Axis I Disorders (SCID). Although the 
DSM-V was recently published, the DSM-IV-TR was used for the purposes of this 
analysis because it was the version used in the initial study. Exclusion criteria included: 
current, active suicidal ideation, medical instability, active substance abuse or 
dependence, and current psychosis or diagnosis of schizophrenia. Participants with a 
history of substance abuse or dependence (i.e. not current) were admitted into the study.  
Table 2. Inclusion and exclusion criteria 
Inclusion Criteria Exclusion Criteria 
 Pregnant 
 18+ years old 
 History of a mood disorder (MDD, 
BP I, BP II, BPNOS) 
 In treatment for management of 
current illness 
 Current, active suicidal ideation 
 Medical instability 
 Active substance abuse or 
dependence  
 Current psychosis or diagnosis of 
schizophrenia 
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Study Measures 
Structured Clinical Interview for DSM-IV Axis I Disorders 
 The SCID-I/P is a semi-structured clinical interview that is used around the world 
in research to diagnose Axis I psychiatric disorders based on the DSM IV-TR (First et al., 
2002; Gorman et al., 2004). Psychiatrists, psychologists, or other researchers who 
complete the necessary training course can administer the SCID. The SCID has been used 
in many studies involving pregnant and postpartum women (Wenzel, Gorman, O’Hara, & 
Stuart, 2001; Gorman et al., 2002; Shuang et al., 2011; O’Hara et al., 2012). For example, 
the SCID was used as part of study by O’Hara et al. to develop a two or three item-
screening questionnaire to detect anxiety and depression in postpartum women (O’Hara 
et al., 2012). The interrater reliabilities based on randomly selected cases was kappa=0.80 
for the MDD module and kappa=1.00 for the GAD module (O’Hara et al., 2012). Wenzel 
et al. obtained 84% agreement between interviewers (kappa=0.67) for diagnoses of MDD 
(Wenzel et al., 2001).  
 Montgomery Asberg Depression Rating Scale 
 The Montgomery Asberg Depression Rating Scale (MADRS), a ten-question 
depression scale, was developed in 1979 by Stuart Montgomery and Marie Asberg. This 
scale was designed to be sensitive to changes due to treatment, particularly 
antidepressants (Montgomery & Asberg, 1979). Scores on the MADRS correlated 
significantly with scores on the HDRS and it was able to detect response to 
antidepressants better than the HDRS (Montgomery & Asberg, 1979). A study by Harris, 
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Huckle, Thomas, Johns, and Fung (1989) compared the MADRS, EPDS, and the Raskin 
3 Area Scale for Depression in women with postpartum depression based on DSM-III 
criteria. They found that all three measures were significantly correlated and that the 
MADRS had excellent specificity (96%) and sensitivity (91%) (Harriet et al., 1989).  
Young Mania Rating Scale 
 The Young Mania Rating Scale (YMRS) is an eleven-item clinician-administered 
rating scale used to screen for mania (Young, Biggs, Ziegler, & Meyer, 1978). The 
YMRS was highly correlated with global rating scales (r=0.88) determined by two 
separate psychiatrists and with two other mania rating scales (Beigel-0.71 and Petterson-
89) (Young et al., 1978). It is able to measure the severity of mania and to detect changes 
in severity as a result of treatment (Young et al. 1978).  
Edinburgh Postnatal Depression Scale  
The Edinburgh Postnatal Depression Scale (EPDS), a 10-question screening tool, 
was developed in 1987 to help physicians diagnose postpartum depression; the scale is 
now used internationally to measure both postpartum depression and depression during 
pregnancy (Cox et al., 1987; Matthey, 2008; Zubaran, Schumacher, Roxo, & Foresti, 
2010). Two major studies have assessed the validity of the use of EPDS in postnatal 
depression (Cox et al., 1987; Cox, Chapman, Murray, & Jones, 1996). The first study, 
conducted in 1987, validated the EPDS using a cohort of 84 women (Cox et al., 1987). 
They showed that the EPDS had “satisfactory validity, split-half reliability and was also 
sensitive to changes in the severity of depression over time” (Cox et al., 1987). In 1996 
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the EPDS was validated for use during pregnancy and the postnatal period (Cox, 
Chapman, Murray, & Jones, 1996). Many studies have shown that a cut-off score of 13 or 
greater indicates probable major depression (Cox et al., 1987; Cox et al., 1996; Matthey, 
2008).  
Inventory of Depressive Symptomatology 
 The Inventory of Depressive Symptomatology (IDS) is a rating scale for 
depression that was created by John Rush and colleagues in the 1980s with the purpose of 
addressing some of the problems with existing rating scales (Rush et al., 1986). The 
version used in this research, the IDS-SR is the self-rated version, which contains thirty 
questions. Rush et al. found that the IDS-SR “had good internal reliability”, significantly 
correlated with two existing rating scales, the HRSD and the BDI, and could evaluate 
depression severity (Rush et al., 1986; Rush, Gullion, Basco, Jarrett, & Trivedi, 1996). A 
study by Yonkers et al. (2001) showed that the IDS performed comparable, if not slightly 
better, than the EPDS in a sample of inner-city postpartum women; the IDS had a higher 
quality index of efficiency, a higher sensitivity, slightly lower specificity, slightly lower 
positive predictive value, and higher negative predicative value.   
Pittsburgh Sleep Quality Index 
 The Pittsburg Sleep Quality Index (PSQI), a self-rated questionnaire used to 
measure sleep quality, was developed in 1988 (Buysse, Reynolds, Monk, Berman, & 
Kupfer, 1988). The PSQI was determined to have acceptable internal homogeneity, test-
retest reliability, and validity (Buysse et al., 1988). A study by Skouteris, Wertheim, 
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Germano, Paxton, and Milgrom (2009) found that the PSQI had good psychometrics in a 
sample of pregnant women.  
Perceived Stress Scale 
 The Perceived Stress Scale (PSS-10) is a ten-item questionnaire designed to 
measure “the degree to which situations in one’s life are appraised as stressful” (Cohen, 
Kamarck, & Mermelstein, 1983). The PSS had good reliability and was correlated with 
depressive and physical symptomatology, life-events score, social anxiety, and utilization 
of health services (Cohen et al., 1983). 
Tennessee Postpartum Stress Scale 
 The Tennessee Postpartum Stress Scale is a twenty-item questionnaire designed to 
measure stress during in postpartum women (Groer, 2005).  
 
Study Design 
 Participants were evaluated as many as six times over a twelve month period; they 
were seen once during each trimester of pregnancy and at one week postpartum, one 
month postpartum, and three months postpartum. We attempted to recruit as many 
women in their first trimester as possible, but many of the women were not recruited until 
their second or third trimester and therefore had a fewer number of visits.  
Screening Visit 
 The first visit for an individual participant was considered her screening visit. For 
example, if a woman was recruited during her third trimester, her first visit was 
considered her screening visit and her third trimester visit. As a result, all of the measures 
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to be collected during both the screening visit and the third trimester visit would be 
collected at this first visit. During the screening visit, the following data was collected: 
blood for genetic studies, Clinical Global Impression (CGI), SCID, Revised NEO 
Personality Inventory (NEO PI-R), mood outcomes, WMDC Questionnaires, mood 
disorder treatment history, and RLCQ.   
First, Second, and Third Trimester Visits 
 The same data was collected at each trimester visit. This included: CGI, mood 
outcomes, MADRS, EPDS, YMRS, IDS, PSQI, PSS, -derived neurotropic factor (BDNF) 
and hormonal/immunological measures, and current medications. The trimester visits are 
referred to as T1, T2, and T3 for the first, second, and third trimesters respectively.  
Postpartum Week One Visit 
 During the one week postpartum visit, the following data was collected: CGI, 
mood outcomes, birth outcomes, MADRS, YMRS, EPDS, IDS, PSQI, PSS, TPSS, 
current medications, and BDNF and hormonal/immunological measures, and current 
medications. The one week postpartum visit is referred to as W1.  
Postpartum Month One Visit 
 During the one month postpartum visit, the following data was collected: CGI, 
mood outcomes, MADRS, YMRS, EPDS, IDS, PSQI, PSS, TPSS, RLCQ, current 
medications, and BDNF and hormonal/immunological measures. The one month 
postpartum visit is referred to as M1.  
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Postpartum Month Three Visit  
At the last visit, the three month postpartum visit, the following data was 
collected: CGI, mood outcomes, MADRS, YMRS, EPDS, IDS, PSQI, PSS, TPSS, 
current medications, and BDNF and hormonal/immunological measures, and current 
medications. The three month postpartum visit is referred to as M3. 
Table 3 shows the data that were completed at each time point.  
Table 3. Data collected at each time point  
 Screening T1 T2 T3 W1 M1 M3 
Blood for Genetic Studies X       
CGI X X X X X X X 
SCID X       
NEO PI-R X       
Mood Outcomes X X X X X X X 
Birth Outcomes     X   
WMDC Questionnaires X       
MADRS  X X X X X X 
Edinburgh  X X X X X X 
YMRS  X X X X X X 
IDS  X X X X X X 
Medications  X X X X X X 
MDTH X       
PSQI  X X X X X X 
RLCQ X     X  
PSS  X X X X X X 
TPSS     X X X 
BDNF, 
Hormonal and 
Immunological Measures 
 X X X X X X 
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Analysis 
Anxiety Prevalence 
 For our analyses, the prevalence of anxiety was determined by two methods. First, 
we estimated the anxiety prevalence based on the number of participants who had a 
lifetime diagnosis of an anxiety disorder based on positive diagnosis from the SCID or 
study psychiatrist at the screening visit. The following anxiety disorders were included 
for this study: obsessive-compulsive disorder (OCD), generalized anxiety disorder 
(GAD), panic disorder, social anxiety, and anxiety disorder not otherwise specified 
(anxiety disorder NOS). We excluded post-traumatic stress disorder (PTSD) because it is 
triggered by a traumatic event as opposed to developing naturally in a susceptible 
individual. We also excluded specific phobias because they are a very limited type of 
anxiety seen only in specific situations. Participants with a lifetime diagnosis of an 
anxiety disorder were analyzed in the Anxiety Diagnosis group and those without a 
diagnosis were analyzed in the No Anxiety Diagnosis group. 
 The second method we used for calculating the prevalence of anxiety was to 
measure the severity of anxiety symptoms at each time point and to identify how many 
participants had significant anxiety symptoms at each time point. While none of the 
scales used in the parent study were specifically geared towards measuring anxiety, two 
of the scales have known anxiety subscales, the EPDS and IDS. We decided to use the 
anxiety subscale of the EPDS as it is used more often in the literature and is a scale 
designed to measure depressive and anxiety symptoms in the perinatal population.   
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EPDS- Anxiety Subscale (EPDS-A) 
 While the EPDS was originally designed with the purpose of screening for 
depression, studies have shown it to be a good screening tool for anxiety as well (Stuart 
et al., 1998; Brouwers, van Baar, & Pop, 2001). Stuart et al. (1998) found that the EPDS 
was highly correlated with the State Trait Anxiety Inventory, STAI, (Speilberger, 
Gorsuch, & Lushene, 1970) one of the primary measures of postpartum anxiety, in 
postpartum women (EPDS and State Anxiety Scale at 30 weeks: r=0.82, p<0.001; EPDS 
and Trait Anxiety Scale at 30 weeks: r=0.81, p<0.001). In addition, studies have found 
that the EPDS contains multiple factors (Pop, Komproe, & van Son, 1992; Brouwers, van 
Baar, & Pop, 2001; Ross, Gilbert Evans, Sellers, Romach, 2003; Jomeen & Martin, 
2005). Pop et al. (1992) found that the EPDS had two factors: depressive symptoms and 
cognitive anxiety. Swalm et al. also found that the EPDS contains two factors: a 
depression factor and an anxiety factor (Swalm, Brooks, Doherty, Nathan, & Jacques, 
2010). Conversely, three other papers found that the EPDS had three factors: a depression 
factor, an anxiety factor, and a third factor, which was based heavily on item 10, A 
question about thoughts of self-harm (Brouwers et al., 2001; Ross et al., 2003; Jomeen & 
Martin, 2005). Because of the anxiety factor in the EPDS, studies have started using that 
subscale to measure anxiety (Matthey, Fisher, & Rowe, 2013 ;Schofield, Battle, Howard, 
& Ortiz-Hernandex, 2014).  
The anxiety subscale of the EPDS, known as the EPDS-A (shown in Table 4), 
consists of three out of the ten questions on the EPDS, numbers 3, 4, and 5 (Pop, 
Komproe, & van Son, 1992; Brouwers et al., 2001; Swalm et al., 2010). Enatescu et al. 
(2014) found that the EPDS-A was highly correlated with the BAI, a widely used anxiety 
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scale in a sample of postpartum women (rho Spearman= 0.729, p<0.001). Matthey (2008) 
conducted a study to determine a cut-off score for the EPDS-A that could used to screen 
for anxiety disorders (GAD, OCD, panic disorder). He found that the optimum cut-off 
score for determining probable anxiety was six or greater (Matthey, 2008). Using a cut-
off score of six the sensitivity was 66.7%, the specificity 88.2%, the positive predictive 
value (percentage of sample soring above the cut-off score who are diagnosed cases) 
31.6%, the negative predictive value 97.0%, and the misclassification 13.4% (Matthey, 
2008). Conversely, two other studies used a cut-off score of four or greater on the EPDS-
A (Swalm et al., 2010; Kingston et al., 2014). Along with the EPDS, Swalm et al. (2010) 
administered a demographic and psychosocial risk factors questionnaire that included 
three anxiety-related questions to women during pregnancy. They defined anxiety 
subscale scores that were higher than the 75
th
 percentile as high and used this to 
determine the cut-off score of four (Swalm et al., 2010). It is not clear why Kingston et 
al. (2014) decided to use a cut-off score of four. We used a cut-off score of six or greater 
to indicate the presence of significant anxiety symptoms. For each time point, the women 
with significant anxiety symptoms, determined by a score of greater than or equal to six 
on the EPDS-A were placed in the Anxiety Symptoms Group while the women without 
significant anxiety symptoms (score of less than six), were placed in the No Anxiety 
Symptoms Group. For the purpose of demographics, we put all the participants who had 
an EPDS-A score of greater than or equal to six at any time point in the Anxiety 
Symptom Group and the participants who never had an EPDS-A score of six or greater in 
the No Anxiety Symptom Group.  
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Table 4. Anxiety subscale of Edinburgh Postnatal Depression Scale  
Anxiety Subscale of EPDS (EPDS-A), 
As you are pregnant or have recently had a baby, we would like to know how you are 
feeling. Please check the answer that comes closest to how you have felt in the past 7 
days, not just how you feel today. 
3. I have blamed myself unnecessarily when things went wrong 
3= Yes, most of the time 
2= Yes, some of the time 
1= Not very often 
0= No, never  
4. I have been anxious or worried for no good reason 
0= No, not at all 
1= Hardly ever 
2= Yes, sometimes 
3= Yes, very often 
5. I have felt scared or panicky for no very good reason 
3= Yes, quite a lot 
2= Yes, sometimes 
1= No, not much 
0= No, not at all 
 
 
Assessment of Suicidality  
In order to assess suicidality, we used the three scales collected in the study that 
contained a question concerning suicidal ideation or self-harm: the EPDS, MADRS, and 
IDS. The EPDS and IDS are self-rated questionnaires, while the MADRS is administered 
by a trained researcher. Question ten in the EPDS asks the participant if the thought of 
harming themselves has occurred to them (Table 5). The answer choices range from 3 
which is “yes, quite often” to 0 which is “never”. For question 10 on the MADRS, the 
interviewer asks the participant if they have had thoughts of suicide or that life is not 
worth living. The answer choices range from 6 “explicit plans for suicide when there is 
an opportunity/active preparations for suicide” to 0 “enjoys life or takes it as it comes”. 
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Lastly, the IDS asks the participant is they have had thoughts of death or suicide with the 
answers ranging from 3 “I think of suicide or death several times a day in some detail or I 
have made specific plans for suicide or have actually tried to take my life” to 0 “I do not 
think of suicide or death”. The questions and answer choices are shown in Table 5.  
 
Table 5. Suicidal ideation questions on depression rating scales  
Edinburgh Postnatal Depression Scale (EPDS), #10 
As you are pregnant or have recently had a baby, we would like to know how you are feeling. 
Please check the answer that comes closest to how you have felt in the past 7 days, not just how 
you feel today. 
1. The thought of harming myself has occurred to me 
3= Yes, quite often 
2= Sometimes 
1= Hardly ever 
0= Never  
Montgomery-Asberg Depression Rating Scale (MADRS), #10 
10. Suicidal thought (feeling  that life is not worth living, that a natural death would be welcome, 
suicidal thoughts, and preparation for suicide). 
0. Enjoys life or takes it as it comes 
1.  
2. Weary of life; only fleeting suicidal thoughts 
3.  
4. Probably better off dead, suicidal thoughts are common, and suicide is considered as 
a possible solution, but without specific plans or intention 
5.  
6. Explicit plans for suicide when there is an opportunity, active preparations for suicide  
Inventory of Depressive Symptomatology (IDS), #18 
Please circle the one response to each item that best describes you for the past seven days 
18. Thoughts of death or suicide:  
0 I do not think of suicide or death 
1 I feel that life is empty or wonder if it’s worth living 
2 I think of suicide or death several times a week for several minutes 
3 I think of suicide or death several times a day in some detail, or I have made   specific 
plans for suicide or have actually tried to take my life  
 
 While none of these questionnaires are specifically suicidality screening 
measures, they all have one question that addresses the issue of self-harm and suicidality. 
Due to the differences in scoring between the three measures, we developed an 
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equivalence scale to compare results between the three screening measures (Table 6).  In 
the studies that used the EPDS to access suicidality, a score of one or above on question 
ten indicated a degree of suicidality while a score of zero indicated no suicidality (Zhong 
et al., 2014). We used a score of zero on the EPDS to indicate no suicidal ideation. 
Comparing the other two measures, an IDS score of zero (I do not think of suicide or 
death) and a MADRS score of zero (enjoys life/takes it as it comes) or one are equivalent 
to an EPDS score of zero. Next, we determined the scores on each measure that indicated 
a mild level of suicidality. A score of one on EPDS, two on the MADRS, and one on the 
IDS indicate a mild level of suicidality. A moderate level of suicidality correspond to an 
EPDS score of two, MADRS score of three, and an IDS score of two. This indicates that 
the patient has thoughts or suicide or self-harm and they are more than fleeting thoughts. 
Lastly, a score of four or above on the MADRS, three on the EPDS, and three on the IDS 
indicate severe suicidality meaning the patient is having thoughts of self-harm, death, and 
suicide very often or has thought of plans for suicide. Two previous studies support the 
use of a score of four or above on the MADRS to indicate severe suicidal ideation and a 
high risk of suicide (Demyttenaere, Desaiah, Raskin, Cairns, & Brecht, 2014; Weisler, 
Montgomery, Earley, Szamosi, Eriksson, 2014).   
 
Table 6. Equivalent scores for three measures with suicidality questions 
Degree of Suicidality MADRS #10 Score EPDS #10 Score IDS #18 Score 
None 0/1 0 0 
Mild  2 1 1 
Moderate  3 2 2 
Severe 4-6 3 3 
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Statistics  
 Descriptive statistics were used to examine the demographics of the anxiety and 
no anxiety groups. Chi-square tests were used to determine if the two groups significantly 
differed based on age, race, educational attainment, marital status, gravidity, and smoking 
during pregnancy; p values were two tailed with significance defined as p less than 0.05. 
Descriptive statistics were used to determine the prevalence of mood and anxiety 
disorders and comorbidity of the two in our study population.  We calculated the 
prevalence of significant anxiety symptoms at each time point, as well as the current and 
lifetime prevalence of anxiety disorders based on diagnosis. Using binomial tests we 
compared the prevalence of significant anxiety symptoms at each time point to the 
prevalence of current anxiety to see if there was a statistically significant difference.  
Due to the fact that not all women completed every visit, there were significant 
gaps in the data. In order to see if this impacted our results, we grouped all of the 
participants who were present at T2, T3, and M1. First, we calculated the anxiety 
prevalence based on symptoms, as determined by EPDS, at each time point and the 
prevalence of a current or lifetime diagnosis of anxiety for all of the participants. Next, 
we did the same calculations but only included the participants who were present at the 
T2, T3, and M1 visits. We then compared the data from all of the participants with the 
data from the participants who were present at all three of the time periods we selected; 
we did this by using binomial tests to compare the proportions.  
Next, we conducted various analyses in order to test our hypothesis. First, we 
used z proportion tests to determine if the percentage of participants with anxiety who 
 42 
were suicidal was greater than the percentage of participants without anxiety who were 
suicidal. Then we used binary logistic regression to further examine whether participants 
with anxiety are at increased risk for suicidality. We conducted binary logistic 
regressions using the presence of any suicidal ideation (MADRS #10≥2, EPDS#10≥1, 
IDS #18≥1). We limited our analyses to the time points T2, T3, and M1 because they had 
the most data.  
 
Human Research Concerns 
The ethical aspect of this research is of particular importance as it involves a 
special research population. According to the federal government, pregnant and lactating 
women are vulnerable research subjects and as a result, there are special guidelines in 
place to protect them (Public Welfare, 2001). Historically, vulnerable populations, 
including pregnant women, were excluded from studies, however, the exclusion of these 
populations puts them at a disadvantage in terms of research. The first criterion is that 
appropriate research is conducted on animals and non-pregnant women before it is 
conducted on pregnant women (Schwenzer, 2008). In addition, the risk to the fetus must 
be minimized in the study (Schwenzer, 2008). Lastly, pregnant women should be 
excluded from studies if there is no potential medical benefit to the women and there are 
potential risks to the fetus (Schwenzer, 2008). 
The parent study involved minimal risk to the patients as the study involved 
gathering information and drawing blood from the patient. Phlebotomy posed the most 
risk to the patient, however the risk is the same as having routine prenatal blood work 
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done. The Johns Hopkins Medicine and the UNC Institutional Review Boards approved 
the parent study.    
RESULTS 
 A total of 91 women participated in this study with a total of 93 pregnancies; two 
of the women participated in the study twice during two separate pregnancies. For the 
purposes of this analysis, only one of the two pregnancies for the women who were in the 
study twice was included. Of the 91 women, 89 were followed at JHU, while two were 
followed at UNC.  
 
Demographics  
Table 7 details the demographic data for all study participants. The average age 
was 30.5±6.3 years. The majority of the participants were White, non-Hispanic, married, 
and college graduates who were multigravidae and did not smoke during pregnancy.   
Next, we separated the participants into two groups based on the presence or 
absence of anxiety. Those with a lifetime diagnosis of an anxiety disorder(s) were placed 
in the Anxiety Diagnosis Group, while those without anxiety disorders were in the No 
Anxiety Diagnosis Group. The average age of the participants in the Anxiety Diagnosis 
Group was 31.2±5.6 versus 29.7±6.9 in the No Anxiety Diagnosis Group. Overall, the 
Anxiety Diagnosis Group was older with 8.9% of the participants over the age of 40 and 
11.1% between the age of 18 and 24 compared to 2.2% over the age of 40 and 23.9% 
between the ages of 18-24 in the No Anxiety Diagnosis Group. In both groups the 
majority of participants were White, Non-Hispanic; however, the Anxiety Diagnosis 
Group had a higher percentage of White, Non-Hispanic participants than the No Anxiety 
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Diagnosis Group. The Anxiety Diagnosis Group had higher level of educational 
attainment: 71.1% of participants in the Anxiety Diagnosis Group had at least a 
Bachelor’s degree compared to 38.7% in the No Anxiety Diagnosis Group. In addition, 
22.7% of the No Anxiety Diagnosis Group did not finish high school compared to 13.3% 
of the Anxiety Diagnosis Group. The level of educational attainment was significantly 
different between the two groups (p=0.030). The women in the Anxiety Diagnosis Group 
were more likely to be married than those in the No Anxiety Diagnosis Group (73.3% 
compared to 57.8%) but this was not statistically significant. There was a significant 
difference in the women’s gravidity between the two groups (p=0.34); women in the 
Anxiety Diagnosis Group were more likely to be pregnant with their first child. Lastly, 
more women in the No Anxiety Diagnosis Group smoked during pregnancy than in the 
Anxiety Diagnosis Group (22.5% compared to 11.4%). The two groups significantly 
differed on both educational attainment and gravidity and as a result, these were 
considered confounders for anxiety diagnosis groups.  
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Table 7. Demographics based on presence or absence of anxiety diagnosis. Anxiety 
Diagnosis Group includes participants who have a current or lifetime diagnosis of an 
anxiety disorder and No Anxiety Diagnosis includes participants who have never been 
diagnosed with an anxiety disorder 
 
 
Characteristic 
 
No. of 
subjects (%) 
Anxiety Diagnosis 
No. of subject with 
anxiety (%) 
No Anxiety Diagnosis 
No. of subjects without 
anxiety (%) 
 
Analysis 
Age (years)  
   18-24 
   25-29 
   30-34 
   35-39 
   ≥ 40 
(n=91) 
16 (17.6) 
25 (27.5) 
23 (25.3) 
22 (24.2) 
5 (5.5) 
(n=45) 
5 (11.1) 
15 (33.3) 
12 (26.7) 
9 (20.0) 
4 (8.9) 
 
(n=46) 
11 (23.9) 
10 (21.7) 
11 (23.9) 
13 (28.3) 
1 (2.2) 
 
χ
2
=20.349 
p=0.621 
Race/ethnicity   
   White, Non-Hispanic 
   Black, Non-Hispanic 
   Hispanic 
   Asian/ Pacific Islander 
   Other 
(n=91) 
64 (70.3) 
20 (22.0) 
1 (1.1) 
3 (3.3) 
3 (3.3) 
(n=45) 
34 (75.6) 
6 (13.3) 
1 (2.2) 
2 (4.4) 
2 (4.4) 
(n=46) 
30 (65.2) 
14 (30.4) 
0 (0.0) 
1 (2.2) 
1 (2.2) 
 
χ
2
=5.106 
p=0.277 
Maternal Education  
   Did not finish high school 
   High school or GED 
   Associates degree (2 yr college) 
   Bachelor’s degree (4 yr college) 
   Graduate or professional degree 
(n=89) 
16 (18.0) 
13 (14.6) 
11 (12.4) 
18 (20.2) 
31 (34.8) 
(n=45) 
6 (13.3) 
3 (6.7) 
4 (8.9) 
13 (28.9) 
19 (42.2) 
(n=44) 
10 (22.7) 
10 (22.7) 
7 (15.9) 
5 (11.4) 
12 (27.3) 
 
χ
2
=10.714 
p=0.030* 
Marital Status  
   Married 
   Co-habitating (not married) 
   Single (never married) 
   Divorced 
(n=90) 
59 (65.6) 
16 (17.8) 
14 (15.6) 
1 (1.1) 
(n=45) 
33 (73.3) 
8 (17.8) 
4 (8.9) 
0 (0.0) 
(n=45) 
26 (57.8) 
8 (17.8) 
10 (22.2) 
1 (2.2) 
 
χ
2
=4.402 
p=0.221 
Gravidity  
   Primigravidae 
   Multigravidae 
(n=87) 
29 (33.3) 
58 (66.7) 
(n=43) 
19 (44.2) 
24 (55.8) 
(n=44) 
10 (22.7) 
34 (77.3) 
 
χ
2
=4.506 
p=0.034* 
Smoking  
   Smoked during pregnancy 
(n=84) 
14 (16.3) 
(n=44) 
5 (11.4) 
(n=40) 
9 (22.5) 
χ
2
=1.871 
p=0.171 
*p<0.05 
 
 Table 8 details the demographics of participants separated into Anxiety 
Symptoms and No Anxiety Symptoms Groups based on severity of anxiety symptoms, 
rather than diagnosis, as determined by a score of six or more on the EPDS-A. The 
Anxiety Symptoms Group included 53 participants, while the No Anxiety Symptoms 
Group included 38 participants. The average age of participants in the Anxiety Symptoms 
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Group was 30.3±6.5 and the average age in No Anxiety Symptoms Group was 30.9±6.0. 
The main difference was there were more black, non-Hispanic, women in the Anxiety 
Symptoms Group than the No Anxiety Symptoms Group. There was a statistically 
significant difference in the race of the two groups (p<0.05) and as a result, race was 
considered a confounder for anxiety groups based on symptoms. 
There were distinct differences in participants with anxiety depending on if we 
used diagnoses (Table 7) or anxiety symptoms as determined by the anxiety subscale of 
the EPDS (Table 8). Our results show that more women with at least a bachelor’s degree 
were diagnosed with anxiety (Anxiety Diagnosis Group) than experienced anxiety 
symptoms (Anxiety Symptoms Group). Conversely, fewer women who did not finish 
high school were diagnosed with anxiety (Anxiety Diagnosis Group) than experienced 
anxiety symptoms (Anxiety Symptoms Group).  In addition, a higher proportion of 
primigravidae women were diagnosed with anxiety than multigravidae women: 65.5% 
versus 41.4% (Table 6). However, the proportion of primigravidae women who 
experienced anxiety symptoms was similar to the proportion of multigravidae women 
who experienced anxiety (62.1% versus 56.9%). 
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Table 8. Demographics based on presence or absence of significant symptoms of 
anxiety. The Anxiety Symptoms Group is all participants with an EPDS-A score of ≥6 at 
a minimum of one time point and the No Anxiety Symptoms Group is the participants 
who never had an EPDS-A score of ≥6 
 
Characteristic 
 
No. of 
subjects 
(%) 
Anxiety Symptoms 
No. of subject with 
anxiety (%) 
No Anxiety Symptoms 
No. of subjects without 
anxiety (%) 
 
Analysis 
Age (years)  
   18-24 
   25-29 
   30-34 
   35-39 
   ≥ 40 
(n=91) 
16 (17.6) 
25 (27.5) 
23 (25.3) 
22 (24.2) 
5 (5.5) 
(n=53) 
12 (22.6) 
12 (22.6) 
14 (26.4) 
11 (20.8) 
4 (7.5) 
(n=38) 
4 (10.5) 
13 (34.2) 
9 (23.7) 
11 (28.9) 
1 (2.6) 
 
χ
2
=18.996 
p=0.701 
Race/ethnicity   
   White, Non-Hispanic 
   Black, Non-Hispanic 
   Hispanic 
   Asian/ Pacific Islander 
   Other 
(n=91) 
64 (70.3) 
20 (22.0) 
1 (1.1) 
3 (3.3) 
3 (3.3) 
(n=53) 
35 (66.0) 
15 (28.3) 
0 (0.0) 
0 (0.0) 
3 (5.7) 
(n=38) 
29 (76.3) 
5 (13.2) 
1 (2.6) 
3 (7.9) 
0 (0.0) 
 
χ
2
=10.372 
p=0.035* 
Maternal Education  
   Did not finish high school 
   High school or GED 
   Associates degree (2 yr college) 
   Bachelor’s degree (4 yr college) 
   Graduate or professional degree 
(n=89) 
16 (18.0) 
13 (14.6) 
11 (12.4) 
18 (20.2) 
31 (34.8) 
(n=52) 
10 (19.2) 
9 (17.3) 
7 (13.5) 
11 (21.2) 
15 (28.8) 
(n=37) 
6 (16.2) 
4 (10.8) 
4 (10.8) 
7 (18.9) 
16 (43.2) 
 
χ
2
=2.197 
p=0.700 
Marital Status  
   Married 
   Co-habitating (not married) 
   Single (never married) 
   Divorced 
(n=90) 
59 (65.6) 
16 (17.8) 
14 (15.6) 
1 (1.1) 
(n=53) 
31 (58.5) 
11 (20.8) 
10 (18.9) 
1 (1.9) 
(n=37) 
28 (78.4) 
5 (13.5) 
4 (10.8) 
0 (0.0) 
 
χ
2
=3.232 
p=0.357 
Gravidity  
   Primigravidae 
   Multigravidae 
(n=87) 
29 (33.3) 
58 (66.7) 
(n=51) 
18 (35.3) 
33 (64.7) 
(n=36) 
11 (30.6) 
25 (69.4) 
 
χ
2
=0.213 
p=0.644 
Smoking  
   Smoked during pregnancy 
(n=84) 
14 (16.3) 
(n=49) 
8 (16.3) 
(n=35) 
6 (17.1) 
χ
2
=0.010 
p=0.921 
*p<0.05 
 
Prevalence of Psychiatric Disorders 
Table 9 shows the prevalence of mood disorders in the entire sample. Twenty-
nine of the participants (31.9%) had Bipolar Disorder (BPI 14.5%, BPII 11.0%, and 
BPNOS 6.6%), while 62 (68.1%) had Major Depressive Disorder.   
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Table 9. Prevalence of mood disorders (n=91) 
Mood Disorder No. of subjects (%)   
BPAD 
     BP I 
     BP II 
     BPNOS 
29 (31.9) 
     13 (14.3) 
     10 (11.0) 
     6 (6.6) 
MDD  62 (68.1) 
 
Of the 91 participants, 45 (49.5%) had a lifetime diagnosis of an anxiety disorder 
and 30 (33.0%) had a current diagnosis of an anxiety disorder (Table 10). The specific 
prevalence rates, shown in Table 9, were as follows: GAD 20.9%, panic disorder 35.2%, 
OCD 9.9%, social anxiety 7.7% and Anxiety NOS 5.5%.  
 
Table 10. Prevalence of anxiety disorders based on lifetime diagnosis (n=91) 
Anxiety Disorder No. of subjects (%)  
GAD 19 (20.9) 
Panic Disorder 32 (35.2) 
OCD 9 (9.9) 
Social Anxiety 7 (7.7) 
Anxiety NOS 5 (5.5) 
Diagnosis of any anxiety disorder 45 (49.5) 
  
 Table 11 shows the prevalence of comorbidity between mood disorders and 
anxiety disorders. Out of the 29 women with BPAD, 14 (48.3%) had a diagnosis of one 
or more anxiety disorders and 6 (20.7%) had a diagnosis of two or more anxiety 
disorders. Out of the 62 women with MDD, 32 (51.6%) had a diagnosis of one of more 
anxiety disorders and 15 (24.2%) had a diagnosis of two or more anxiety disorders. 
Overall, 45 (49.5%) had a diagnosis of at least one anxiety disorder and 21 (23.1%) had a 
diagnosis of two or more anxiety disorders.  
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Table 11. Comorbidity of mood disorders and anxiety disorders (n=91) 
Mood Disorder + ≥1 Anxiety Disorder + ≥2 Anxiety Disorder 
BPAD (n=29) 13 (44.8) 6 (20.7) 
MDD (n=62) 32 (51.6) 15 (24.2) 
 
Anxiety Symptoms 
 We compared the percentage of women who experienced significant symptoms of 
perinatal anxiety to the percentage of women diagnosed with anxiety disorders. Binomial 
tests demonstrated that the prevalence of significant anxiety symptoms was significantly 
different from the prevalence of current anxiety diagnosis only at the one week 
postpartum visit (z=-3.37, p<0.01, two-tailed). The point prevalence for significant 
anxiety symptoms at each time point is shown in Figure 2. The current and lifetime 
diagnosis percentages are based on diagnoses made either by SCID or the study 
psychiatrist, while the time point percentages are based on the percentage of women with 
a score of six or greater on the EPDS-A at that specific time point. A total of 49.5% had a 
lifetime diagnosis of anxiety disorders and 33.0% had a current diagnosis of anxiety 
disorders at the time of their screening for the study. The prevalence of anxiety symptoms 
was as follows: T1 26.7%, T2 36.5%, T3 36.4%, W1 9.1%, M1 24.1%, and M3 37.5%.  
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Figure 2. Anxiety prevalence. Lifetime and current diagnosis indicates participants had 
a diagnosed anxiety disorder and anxiety at each time point indicates a score of six or 
greater on the EPDS-A. N values vary for each time point. 
 Figure 3 shows the percentage of lifetime anxiety diagnosis, current anxiety 
diagnosis, and anxiety symptoms at three time points. Unlike Figure 2, only the 35 
participants who completed all three of these visits, T2, T3, and M1, were included in 
these calculations (Figure 3). The lifetime anxiety diagnosis prevalence was 51.4% and 
the current anxiety diagnosis prevalence was 31.4% (Figure 3); neither of these 
percentages was statistically different than the values for the data with all the participants 
as shown in Figure 2 (p>0.05). The prevalence of significant anxiety symptoms was as 
follows: T2 34.3%, T3 25.7%, and M1 22.9% (Figure 3). These values were also not 
statistically different than the percentages with all of the participants (p>0.05).  
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Figure 3. Anxiety prevalence of participants for whom we have data for at T2, T3, 
and M1 (n=35). Lifetime and current diagnosis indicates participants had a diagnosed 
anxiety disorder and anxiety at each time point indicates a score of six or greater on the 
EPDS-A.  
 
 In order to determine how much of the EPDS score was determined by the three-
question anxiety subscale, we calculated the proportion of the total EPDS score 
contributed by the EPDS-A score. Figure 4 shows the percent contribution of the EPDS-
A subscale score to the overall EPDS score: T2 47.5%, T3 44.0%, and M1 44.7%.  
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Figure 4. Mean proportion of the total score on the Edinburgh Postnatal Depression 
Scale contributed by the EPDS-A at T2, T3, and M1. Anxiety subscale score is the 
sum of scores on questions 3,4,5 on the EPDS; T2 N=54, T3 N=79, M1 N=60 
 
Anxiety and Suicidal Thoughts 
 After determining the prevalence of anxiety symptoms, we examined whether 
suicidality was associated with anxiety symptoms. Figure 5 shows the prevalence of 
suicidal ideation based on MADRS question ten, EPDS question ten, and IDS question 
eighteen. We used a cut-off score of greater than or equal to two on the MADRS question 
ten, greater than or equal to one on the EPDS question ten, and greater than or equal to 
one on the IDS question eighteen. The prevalence of suicidal ideation for each of the 
scales increased throughout pregnancy and then decreased significantly at one week 
postpartum, but then increased again at one month postpartum. At three month 
postpartum, the MADRS and EPDS showed that suicidal ideation decreased, however it 
slightly according to the IDS. Of all the time points, the highest prevalence of suicidal 
ideation was at the third trimester for all three scales. 
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Figure 5. Prevalence of suicidal ideation at each time point as determined by 
MADRS question 10, EPDS question 10, and IDS question 18. The following cut-offs 
were used to determine the presence of any suicidal ideation: MADRS #10≥2, EPDS #10 
≥1, and IDS #18 ≥ 1 
Suicidal Ideation Based on MADRS 
Table 12 shows the prevalence of anxiety symptoms among participants with any 
level of suicidal ideation as determined by a score of two or greater on MADRS question 
ten. At T2, T3, M1, and M3 there was a higher percentage of suicidal women who were 
anxious than suicidal women who were not anxious.  
 
Table 12. Anxiety prevalence among participants with any suicidal ideation based 
on MADRS #10. Presence of suicidal ideation based on a MADRS #10 score of greater 
than or equal to two and anxiety symptoms based on an EPDS-A score of six or greater 
 
 
T1 
(n=13) 
T2 
(n=52) 
T3 
(n=76) 
W1 
(n=43) 
M1 
(n=57) 
M3 
(n=54) 
Suicidal 0 7 (13.5) 13 (17.1) 1 (2.3) 10 (17.5) 8 (14.8) 
   Anxiety  5 (71.4) 9 (69.2) 0 (0.0) 6 (60.0) 7 (87.5) 
   No Anxiety  2 (28.6) 4 (30.8) 1 (100.0) 4 (40.0) 1 (12.5) 
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The percentages of women in the Anxiety Symptom Group and No Anxiety 
Symptom Group who had any degree of suicidal ideation at each time point are depicted 
in Table 13. The proportion of women in the Anxiety Symptom Group who were suicidal 
was significantly greater than the proportion of women in the No Anxiety Symptom 
Group who were suicidal at T2, T3, M1, and M3 (z test).  
 
Table 13. Prevalence of suicidality among participants with and without anxiety 
symptoms based on EPDS-A. Presence of suicidal ideation based on a MADRS 
question 10 score of greater than or equal to two and anxiety symptoms based on an 
EPDS-A score of six or greater  
 T1 
(n=13) 
T2 
(n=52) 
T3 
(n=76) 
W1 
(n=43) 
M1 
(n=57) 
M3 
(n=54) 
Anxiety 4 19 28 3 14 20 
    Suicidal 0 5 (26.3)* 9 (32.1)* 0 (0.0) 6 (42.9)* 7 (35.0)* 
No Anxiety 9 33 48 40 43 34 
    Suicidal 0 2 (6.1) 4 (8.3) 1 (2.5) 4 (9.3) 1 (2.9) 
*p<0.05 
 
We also examined the proportions of women who were moderately or severely 
suicidal, as determined by a score of greater than or equal to three or greater than or equal 
to four respectively on MADRS question ten, and found that the Anxiety Symptom and 
No Anxiety Symptom group did not statistically differ at any time point.  
  A logistic regression was performed to determine the effects of anxiety, based on 
EPDS-A scores, and race on the likelihood that participants were suicidal (score of two or 
greater on MADRS question ten) at T2, T3, and M1. The logistic regression model for 
MADRS at T2 was not statistically significant. However, at T3 the logistic regression 
model was statistically significant, χ2(5) = 19.102, p < .005 and explained 37.1% 
(Nagelkerke R
2
) of the variance in suicidality. The model correctly classified 88.2% of 
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cases. The sensitivity was 46.2%, specificity was 96.8%, positive predictive value was 
75%, and the negative predictive value was 89.7%. As shown in Table 14 only anxiety, 
not race, added significantly to the model. For each increase in the EPDS-A score by one, 
the odds of being suicidal increased by 2.106. The results for the logistic regression 
model at M1 (not shown) were very similar to the results for the model at T3. The model 
was statistically significant χ2(5) = 12.302, p < .05 and explained 32.1% (Nagelkerke R2) 
of the variance in suicidality. Again, only anxiety added significantly to the model 
(p<0.05, OR=2.057, 95% CI 1.179-3.586). 
 
Table 14. Logistic regression predicting the likelihood of suicidality, using the 
MADRS, at T3 based on anxiety symptoms and race. Suicidality determined using a 
score of two or greater on MADRS question ten and anxiety symptoms determined by a 
score of six or greater on the EPDS-A  
  
B 
 
SE 
 
Wald 
 
df 
 
p 
 
OR 
95% CI for 
Odds Ratio 
Lower  Upper 
EPDS-A  .745 .256 8.442 1 0.004 2.106 1.274 3.481 
Race- White   .612 4     
Race- Black .605 .773 .612 1 .434 1.831 .402 8.337 
Race- Hispanic 24.74 40192 .00 1 1.00
 
5.5x10
10
 .00  
Race- Asian -18.84 38187 .00 1 .99 .00 .00  
Race- Other -19.16 28420 .00 1 .99 .00 .00  
Constant -5.77 1.612 12.810 1 .000 .003   
Note: Race is comparing Black, Hispanic, Asian, and Other to White  
Suicidal Ideation Based on EPDS 
Table 15 shows the prevalence of anxiety symptoms among participants with any 
level of suicidal ideation (score of greater than or equal to one) and among participants 
with at least moderate suicidal ideation (score of greater than or equal to two), as 
determined by question 10 of the EPDS. For any suicidal ideation there was a higher 
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percentage of suicidal women from the Anxiety Symptom Group than suicidal women 
from the No Anxiety Symptom Group at T1, T2, T3, and M3. For moderate suicidal 
ideation, the percentage of suicidal women from the Anxiety Symptom Group was 
greater than the percentage of suicidal women from the No Anxiety Symptom Group at 
every time point except for W1 when no one was moderately suicidal.  
Table 15. Prevalence of anxiety symptoms among participants with suicidal ideation 
based on EPDS. Presence of any suicidal ideation based on an EPDS question ten score 
of greater than or equal to one and presence of moderate suicidal ideation score of greater 
than or equal to two; presence of anxiety symptoms based on an EPDS-A score of six or 
greater 
  T1 
(n=15) 
T2 
(n=52) 
T3 
(n=77) 
W1 
(n=44) 
M1 
(n=58) 
M3 
(n=56) 
Score ≥1 
Any 
suicidal 
ideation 
Suicidal 1 (6.7) 8 (15.4) 19 (24.7) 7 (15.9) 10 (17.2) 6 (10.7) 
  Anxiety 1 (100.0) 5 (62.5) 14 (73.7) 3 (42.9)   5 (50.0) 4 (66.7) 
  No Anxiety 0 (0.0) 3 (37.5) 5 (26.3)   4 (57.1) 5 (50.0) 2 (33.3) 
Score ≥2 
Moderate 
suicidal 
ideation 
Suicidal  1 (6.7) 2 (3.8) 4 (5.2) 0 (0.0) 3 (5.2) 3 (5.4) 
  Anxiety 1 (100.0) 2 (100.0)  3(75.0) 0 3 (100.0) 3 (100.0) 
  No Anxiety 0 (0.0) 0 (0.0)  1 (25.0) 0 0 (0.0) 0 (0.0) 
 
 
Table 16 shows the percentages of women from the Anxiety Symptom and No 
Anxiety Symptom groups who had any degree of suicidal ideation and the women who 
had at least moderate suicidal ideation. The percentage of anxious women (Anxiety 
Symptom Group) who were suicidal was greater than the percentage of non-anxious 
women (No Anxiety Symptom) who were suicidal at every time point. Based on a z 
proportions test there was a statistically significant difference in the proportion of women 
from the Anxiety Symptom Group who were suicidal and the proportion of women from 
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the No Anxiety Symptom Group who were suicidal at T3, W1, and M1. The percentage 
of women from the Anxiety Symptom Group who were suicidal was greater than the 
percentage of women from the No Anxiety Symptom Group who were suicidal at every 
time point, except W1 when no one was moderately suicidal. The proportion of women in 
the Anxiety Symptom Group who were suicidal was statistically different than the 
proportion of women in the No Anxiety Symptom Group who were suicidal at M1 and 
M3.  
Table 16. Prevalence of suicidality, based on EPDS, among participants with and 
without anxiety symptoms based on EPDS-A. Presence of any suicidal ideation based 
on an EPDS question ten score of greater than or equal to one and presence of moderate 
suicidal ideation based on a score of greater than or equal to two; presence of anxiety 
symptoms based on an EPDS-A score of six or greater 
  T1 
(n=13) 
T2 
(n=52) 
T3 
(n=76) 
W1 
(n=43) 
M1 
(n=57) 
M3 
(n=54) 
Score ≥1 
Any 
suicidal 
ideation 
Anxiety 4 19 28 4 14 21 
  Suicidal 1 (25.0) 5 (26.3) 14 (50.0)* 3 (75.0)* 5 (35.7)* 4 (19.1) 
No Anxiety 11 33 49 40 44 35 
  Suicidal 0 (0.0) 3 (9.1) 5 (10.2) 4 (10.0) 5 (11.4) 2 (5.7) 
Score ≥2 
Any 
suicidal 
ideation 
Anxiety 4 19 28 4 14 21 
  Suicidal 1 (25.0) 2 (10.5) 3 (10.7) 0 (0.0) 3 (21.4)* 3 (14.3)* 
No Anxiety 11 33 49 40 44 35 
  Suicidal 0 (0.0) 0 (0.0) 1 (2.0) 0 (0.0) 0 (0.0) 0 (0.0) 
*p<0.05 
 
There were no participants who were severely suicidal based on a score of three on EPDS 
question 10.  
A logistic regression was performed to determine the effects of significant anxiety 
symptoms, based on EPDS-A scores, and race on the likelihood that participants were 
suicidal, based on a score of greater than or equal to one on EPDS question 10, at T2, T3, 
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and M1. The logistic regression model for EPDS at T2 was not statistically significant. 
The logistic regression model for T3 was statistically significant, χ2(5) = 15.949, p < .005 
and explained 27.8% (Nagelkerke R
2
) of the variance in suicidality (shown in Table 17). 
The model correctly classified 80.5% of cases. The sensitivity was 31.6%, specificity was 
96.6%, positive predictive value was 75%, and the negative predictive value was 81.2%. 
As shown in Table 16 only anxiety symptoms, not race, added statistically significantly 
to the model. For each increase in the EPDS-A score by one, the odds of being suicidal 
increased by 1.758. The logistic regression model for EPDS at M1 was not statistically 
significant. 
Table 17. Logistic regression predicting the likelihood of suicidality, using the 
EPDS, at T3 based on anxiety and race. Suicidality determined by a score of one or 
greater on question ten of the EPDS and presence of anxiety symptoms determined by a 
score of greater than or equal to six on the EPDS-A 
  
B 
 
SE 
 
Wald 
 
df 
 
p 
 
OR 
95% CI for 
Odds Ratio 
Lower  Upper 
EPDS-A  .564 .187 9.114 1 0.003 1.758 1.219 2.535 
Race- White   1.975 4 .740    
Race- Black .696 .667 1.090 1 .297 2.007 .543 7.419 
Race- Hispanic -18.76 40193 .00 1 1.00
 
.00 .00  
Race- Asian -1.60 1.49 1.161 1 .281 4.96 .269 91.25 
Race- Other -19.88 28420 .00 1 .999 .00 .00  
Constant -4.14 1.104 14.066 1 .000 .016   
Note: Race is comparing Black, Hispanic, Asian, and Other to White  
Suicidal Ideation Based on IDS 
 Table 18 shows the percentage of suicidal women, based on the IDS question 
eighteen, from the Anxiety Symptom and No Anxiety Symptoms Groups. The presence 
of any suicidal ideation was determined by a score of greater than or equal to one, while 
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the presence of moderate suicidal ideation was determined by a score of greater than or 
equal to two. The percentage of suicidal women who were from the Anxiety Symptoms 
Group was greater than the percentage of suicidal women who were from the No Anxiety 
Symptoms Group at every time point except for T2. The percentage of moderately 
suicidal women who in the Anxiety Symptoms Group was only greater than the 
percentage of moderately suicidal women who were in the No Anxiety Symptoms Group 
at M3. No women were moderately suicidal, based on the IDS, at T1, W1, or M1.   
Table 18. Anxiety prevalence among participants with suicidal ideation based on the 
IDS. Presence of any suicidal ideation based on a IDS #18 score of greater than or equal 
to one and presence of moderate suicidal ideation based on score of greater than or equal 
to two; anxiety symptoms based on an EPDS-A score of six or greate 
 T1 
(n=15) 
T2 
(n=52) 
T3 
(n=75) 
W1 
(n=42) 
M1 
(n=58) 
M3 
(n=55) 
Score≥1 
Any 
suicidal 
ideation 
Suicidal 1 (6.7) 4 (7.7) 11 (14.7) 1 (2.4) 4 (17.2) 4 (10.7) 
  Anxiety   1 (100.0) 2 (50.0) 6 (73.7) 1 (100.0) 4 (100.0) 4 (100.0) 
  No Anxiety 0 (0.0) 2 (50.0) 5 (26.3) 0 (0.0) 0 (0.0) 0 (0.0) 
Score≥2 
Moderate 
Suicidal 
ideation 
Suicidal 0 (0.0) 1 (3.8) 2 (5.2) 0 (0.0) 0 (0.0) 2 (5.4) 
  Anxiety  0 (0.0) 1 (50.0)   2(100.0) 
  No Anxiety  1 (100.0) 1 (50.0)   0 (0.0) 
 
 
 Table 19 shows the prevalence of suicidality, as determined by IDS question 
eighteen, among participants from the Anxiety Symptom and No Anxiety Symptom 
groups. The percentage of women from the Anxiety Symptom Group who were suicidal 
was greater than the percentage of women from the No Anxiety Symptom Group who 
were suicidal at every time point. The proportion of women from the Anxiety Symptom 
Group who were suicidal was statistically different than the proportion of women from 
the No Anxiety Symptom Group who were suicidal at W1, M1, and M3. For moderate 
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suicidality, the percentage of women from the Anxiety Symptom Group was only greater 
than the percentage of women from the No Anxiety Symptom Group at T3 and M3. The 
proportion of women from the Anxiety Symptom Group who were moderately suicidal 
was not statistically different than the proportion of women from the No Anxiety 
Symptom Group who were moderately suicidal at any time point.  
Table 19. Prevalence of suicidality, based on IDS, among participants with and 
without symptoms of anxiety. Presence of any suicidal ideation based on an IDS 
question 18 score of greater than or equal to one and presence of moderate suicidal 
ideation based on a score of greater than or equal to two; anxiety symptoms based on an 
EPDS-A score of six or greater 
  T1 
(n=13) 
T2 
(n=52) 
T3 
(n=76) 
W1 
(n=43) 
M1 
(n=57) 
M3 
(n=54) 
Score ≥1 
Any 
suicidal 
ideation 
Anxiety 4 19 28 4 14 21 
  Suicidal 1 (25.0) 2 (10.5) 6 (21.4) 1 (25.0)* 4 (28.6)* 4 (19.1)* 
No Anxiety 11 33 47 38 44 34 
  Suicidal 0 (0.0) 2 (6.1) 7 (14.9) 0 (0.0) 0 (0.0) 0 (0.0) 
Score ≥2 
Any 
suicidal 
ideation 
Anxiety 4 19 28 4 14 21 
  Suicidal 0 (0.0) 0 (0.0) 1 (3.6) 0 (0.0) 0 (0.0) 2 (9.5) 
No Anxiety 11 33 47 38 44 34 
  Suicidal 0 (0.0) 1 (3.0) 1 (2.1) 0 (0.0) 0 (0.0) 0 (0.0) 
*p<0.05 
 
There were no participants who were severely suicidal based on a score of three on IDS 
question eighteen.  
A logistic regression was performed to determine the effects of significant anxiety 
symptoms, based on EPDS-A scores, and race on the likelihood that participants were 
suicidal, based on a score of greater than or equal to one on IDS question 18, at T2. The 
logistic regression model for IDS at T2 was not statistically significant. The logistic 
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regression model for IDS at T3 was also not statistically significant. The logistic 
regression model for M1 was statistically significant, χ2(5) = 21.473, p < .005 and 
explained 78.4% (Nagelkerke R
2
) of the variance in suicidality (shown in Table 20). The 
model correctly classified 96.6% of cases. The sensitivity was 50.0%, specificity was 
100.0%, positive predictive value was 100%, and the negative predictive value was 
96.4%. As shown in Table 19, neither anxiety symptoms nor race added statistically 
significantly to the model.  
 
Table 20. Logistic regression predicting the likelihood of suicidality, using the IDS, 
at M1 based on symptoms of anxiety and race. Suicidality determined by a score of 
greater than or equal to one on IDS question eighteen; presence of anxiety symptoms 
determined by score of greater than or equal to six on the EPDS-A 
  
B 
 
SE 
 
Wald 
 
df 
 
p 
 
OR 
95% CI for 
Odds Ratio 
Lower  Upper 
EPDS-A  30.84 2651 .00 1 .991 2.5x10
13 
.00  
Race- White   .00 4 1.00    
Race- Black 15.81 1914 .00 1 .993 7323040 .00  
Race- Hispanic 195.3 44271 .00 1 .996
 
6.9x10
84 
.00  
Race- Asian 133.7 31360 .00 1 .997 1.1x10
58 
.00  
Race- Other 40.9 2651 .00 1 .999 2.5x10
13 
.00  
Constant -216.6 18561 .00 1 .991 .00   
Note: Race is comparing Black, Hispanic, Asian, and Other to White  
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DISCUSSION 
The objective of this research was to determine if a relationship exists between 
anxiety and suicidality and specifically, if anxiety is a risk factor for suicidality in 
pregnant women with mood disorders. When examining the demographics of women 
who experienced anxiety versus those who did not, based on EPDS-A scores, we found 
some interesting trends. The majority of the younger participants, ages 18-24, were in the 
Anxiety Symptoms Group. This finding supports previous work by Martini et al. (2015) 
who found that low maternal age (below the age of 25) was a risk factor for anxiety 
disorders during the postpartum period (OR 2.16; 95% CI 1.11-4.19). We saw the same 
trend for the oldest participants who were forty or older. However, the proportions of 
women in the age range of 35-39 had equal proportions of women in both groups. 
Swalm et al. (2010) found that first time mothers were 1.6 times more likely to 
experience antenatal anxiety, as determined by an EPDS-A score of greater than or equal 
to four. However, we found that the percentage of primigravidae women who 
experienced anxiety, based on EPDS-A scores, was similar to the percentage of 
multigravidae women who experienced anxiety.  
When comparing the demographics of the Anxiety Symptoms and No Anxiety 
Symptoms groups, we found a significant difference in the race of the two groups. We 
found that a higher percentage of African Americans experienced symptoms of anxiety 
during the perinatal period than were diagnosed with anxiety disorders. This would be 
possible if women were not diagnosed with an anxiety disorder at the screening visit, but 
later developed significant anxiety symptoms. Conversely, we saw that a lower 
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percentage of White, Non-Hispanics experienced symptoms of anxiety than were 
diagnosed with anxiety. Using the World Health Survey Initiative Version of the World 
Health Organization’s Composite International Interview, a diagnostic interview used to 
diagnose DSM-IV-TR disorders, Asnaani et al. (2010) examined the difference in the 
prevalence of anxiety disorders among different races including White Americans, 
African Americans, Hispanic Americans, and Asian Americans. They found that White 
American were more likely to be diagnosed with GAD, panic disorder, and social anxiety 
than the other racial groups. However, African Americans were more likely to be 
diagnosed with PTSD. However, our results show that a lower proportion of Blacks 
(30.0%) were diagnosed with anxiety as compared to Whites (53.1%), but a higher 
proportion of Blacks (75.0%) experienced symptoms of anxiety as compared to Whites 
(54.7%). We did not include a diagnosis of PTSD in the anxiety diagnosis category and if 
the fact that African Americans are more likely to be diagnosed with PTSD is true in our 
study, then this would explain why fewer Africans Americans are diagnosed with anxiety 
than experienced anxiety.  
All of the 91 participants had mood disorders: 31.9% had bipolar disorder and 
68.1% had major depressive disorder. In addition, 49.5% had a lifetime diagnosis of an 
anxiety disorder and 33.0% had a current diagnosis of an anxiety disorder. The 
prevalence of anxiety disorders was as follows: panic disorder 35.2%, GAD 20.9%, OCD 
9.9%, social anxiety 7.7% and Anxiety NOS 5.5%.  
According to the US National Comorbidity Survey Replication, the lifetime 
prevalence of any anxiety disorder for women was 37.3% (Kessler et al., 2012). In 
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addition, the prevalence of anxiety disorders for women was as follows: social anxiety 
(12.3%), GAD (5.5%), panic disorder (4.8%), and OCD (3.0%) (Kessler et al., 2012). 
The Kessler et al. study used the Composite international Diagnostic Interview, a 
structured diagnostic interview used to diagnose DSM-IV-TR disorders (Kessler et al., 
2012). Schofield et al. (2014) determined the prevalence of anxiety disorders using a 
sample of 334 women in a perinatal partial hospitalization program. Anxiety disorder 
diagnoses were determined by clinicians and based on the DSM-IV-TR. A total of 32.3% 
of the participants were diagnosed with an anxiety disorder. Anxiety NOS (6%) was the 
most common, followed by panic disorder (4.2%), OCD (3.9%), social anxiety (1.5%), 
and GAD (0.6%) (Schofield et al., 2014).  
Both the prevalence of any anxiety disorders and the prevalence of each specific 
anxiety disorders, except for social anxiety and anxiety NOS, were higher in our study 
than the other two studies. Not only were the actual values different, but also the rankings 
of the disorders from most to least common were different. The Schofield et al. (2014) 
study was similar to ours due to the fact that they drew from a population of women in a 
treatment program specifically for perinatal psychiatric issues, rather than the general 
public. As a result, we would expect our results to be relatively similar. However, there 
are some distinct differences between their data and ours. First, our overall anxiety 
prevalence is significantly larger. In addition, we found a much higher prevalence of both 
panic disorder and GAD. Interestingly, our prevalence of current anxiety almost exactly 
matches their anxiety diagnosis prevalence (Schofield et al., 2014).  
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Next, we looked individually at the prevalence of anxiety symptoms at each time 
point; the percentage of participants at each time point who experienced symptoms of 
anxiety was as follows: 26.7% at T1, 36.5% at T2, 36.4% at T3, 9.1% at WI, 24.1% at 
M1, and 37.5% at M3. In a study by Swalm et al. (2010), EPDS-A scores were 
significantly higher during the antenatal period than the postpartum period. EPDS-A 
scores decreased significantly over the course of the antenatal period and also over the 
course of the postnatal period (Swalm et al., 2010). Conversely, our results show that 
anxiety increased from T1 to T2 and then stayed approximately the same for the rest of 
pregnancy, dramatically decreased immediately after birth and then continued to increase 
after that. There are three distinct differences however between our study and the study 
by Swalm et al. (2010). First, their study was conducted in Australia and second, they 
recruited patients from the general public, whereas our sample draws from a mood 
disorder population. Lastly, they used a cut-off score of greater than or equal to four on 
the EPDS-A while we used six as the cut-off score. Ross et al. (2003) found that scores 
on the EPDS-A were highest during late pregnancy, between 36-40 weeks of gestation, 
decreased by 6 weeks postpartum, and the lowest at 16 weeks postpartum. Our results 
show that the prevalence of anxiety symptoms is almost identical during mid to late 
pregnancy and three months postpartum. Each study yielded slightly different results, 
which is most likely due to different sampling and study methods. However, one 
commonality between all of the studies is that the end of pregnancy is a time of 
significant anxiety and therefore, women should be screened during this period for 
symptoms of anxiety.  
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 Another way we compared anxiety at different time points was to examine the 
percent contribution of the EPDS-A score to the overall EPDS score. The EPDS-A 
contributed 47.5% at T2, 44.0% at T3, and 44.7% at M1. Ross et al. (2003) found that the 
3-item anxiety subscale of the EPDS accounted for 47% of the total score during the end 
of pregnancy (36-40 weeks of gestation), 38% at six weeks postpartum, and 43% at 
sixteen weeks postpartum. Furthermore, Swalm et al. (2010) determined that the EPDS-A 
comprised 43-50% of the total EPDS score: 50% during pregnancy up until 38 weeks, 
40% between 38 and 40 weeks of pregnancy, and 43% during the first six weeks 
postpartum. The proportion of the EPDS-A score at T2 was lower in our study than in the 
study by Swalm et al (2010). The anxiety subscale proportion during T3 in our study was 
between the values determined during late pregnancy in the other two studies (Ross et al., 
2003; Swalm et al., 2010). In addition, our proportion at M1 was very similar to that 
found by Swalm et al. (2010) up to weeks postpartum, but significantly larger than that 
found by Ross et al. (2003) at six weeks postpartum. Both of the other studies showed 
that the anxiety proportion was lower during the postpartum period than during 
pregnancy, with the exception of the value for 38-40 weeks in the Swalm et al. study 
(2010). Regardless of the slight differences between the proportions, it is clear that 
anxiety accounts for a significant proportion of the total EPDS score and as a result, is a 
significant issue during the entire perinatal period.  
 We used three scales to assess suicidality in our sample and each of the scales 
produced different results. The prevalence of suicidality during pregnancy was as 
follows: T1 0%-6.7%, T2 7.7%-15.4%, and T3 14.7%-24.7%. During the postpartum 
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period, the ranges were as follows: W1 2.3%-15.9%, M1 6.9%-17.5%, and M3 7.3%-
14.8%. It is interesting that there was up to a 13% range in the suicidality at a single time 
point between the scales. We believe the variance between scales is due to two factors: 
first, two of the scales, the IDS and the EPDS, are self-reported while the MADRS is 
administered and second, there is a difference in wording between the three questions. 
Both the IDS and MADRS specifically reference death and suicide while the EPDS only 
references harming oneself.  As a result, we would expect the EPDS to yield the highest 
prevalence of suicidality, determined by the endorsement of question ten. This in fact the 
case for T2, T3, and W1, however, at T1 both the IDS and EPDS yielded the highest 
prevalence and at M1 and M3 the MADRS yielded the highest prevalence.  In addition, 
we might expect the MADRS, which is administered by someone else, to yield the lowest 
prevalence as a result of underreporting due to embarrassment, shame, or other emotions. 
However, the MADRS only yielded the lowest prevalence at two time points, T1 and 
W1.  
 In our study suicidality increased throughout pregnancy, decreased immediately 
after pregnancy, increased at one month postpartum, and then slightly decreased at three 
months postpartum. For all three scales, suicidality was the highest during the third 
trimester. The average prevalence of suicidality was 11.8% during pregnancy and 10.6% 
during the postpartum. Newport et al. (2007) determined the prevalence of suicidality 
during pregnancy to be 16.7% according to the HRSD and 27.8% according to the BDI. 
Similar to our study, this study comprised only participants who were seen at a mental 
health clinic (Newport et al., 2007). However, the levels of suicidality were significantly 
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higher in the study by Newport et al. (2007) than those found in our study.  Again, it is 
possible that the use of different scales led to the different results. It is also possible that 
the population studied by Newport et al. (2007) had a higher severity of disease than our 
population. Lindahl et al. (2005) conducted a literature review of twenty-seven studies 
that examined suicidality during the perinatal period. Suicidality during the postpartum 
period, according to the EPDS question ten, ranged from 4-15.4% (Lindahl et al., 2005). 
The prevalence of suicidality in our study is on the upper end of the range found by 
Lindahl et al. (2005), which probably reflects our mood disorder population. Pope, Xie, 
Sharma, and Campbell (2013), examined the prevalence of suicidality in a sample of 
women with mood disorders in Canada. During the first year postpartum, the prevalence 
of thoughts of self-harm, as determined by question ten on the EPDS, was 16.97% and 
the prevalence of suicidality, based on question three on the HDRS, was 6.16% (Pope et 
al., 2013). Given the similarity between the patient populations, it makes sense that our 
results on the EPDS during the postpartum period were very similar (Pope et al., 2013).   
 Lastly, we examined the association between anxiety symptoms and suicidality. 
In our study, the proportion of women from the Anxiety Symptoms Group who were 
suicidal was statistically significantly larger than the proportion of women from the No 
Anxiety Symptoms Group who were suicidal at T2, T3, M1, and M3 based on the 
MADRS (score of greater than or equal to two, T2, W1, and M1 based on the EPDS 
(score of greater than or equal to one), and W1, M1, and M3 on the IDS (score of greater 
than or equal to one). The proportions were statistically significant across all three 
measures at M1. We also specifically tested whether those with significant anxiety 
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symptoms were statistically more likely to be suicidal. Based on the MADRS, those with 
significant anxiety symptoms were significantly more likely to be suicidal at T3 (OR 
2.106, 95% CI 1.274-3.481) and at M1 (OR 2.057, 95% CI 1.179-3.586). Based on the 
EPDS, those with significant anxiety symptoms were statistically more likely to be 
suicidal at T3 (OR 1.758, 95% CI 1.219-2.535).  However, based on the IDS those with 
significant anxiety symptoms were not statistically more likely to be suicidal at any time 
point. These results show that not only is there is a definitive association between 
significant anxiety symptoms and suicidality, but also that the presence of significant 
anxiety symptoms is a risk factor for suicidality during the perinatal period.  
 Other studies have also shown that patients with anxiety are more likely to be 
suicidal. The National Comorbidity Survey- Replication found that certain anxiety 
disorders predicted suicidal ideation and suicide attempts (Cougle et al., 2009). This 
study showed that for women, social anxiety (OR 1.86; 95% CI 1.43-2.42), panic 
disorder (OR 1.55; 95% CI 1.16-2.08), PTSD (OR 1.54; 95% CI 1.13-2.10), and GAD 
(OR 1.84; 95% CI 1.40-2.43) were all significant risk factors for suicidal ideation. 
Further, social anxiety (OR 1.96; 95% CI 1.25-3.05), GAD (OR 2.02; 95% CI 1.42-2.86), 
and PTSD (OR 1.99; 95% CI 1.38-2.88) were risk factors for suicide attempts (Cougle et 
al., 2009). Specifically in the perinatal population, Schofield et al. (2014) determined that 
perinatal patients with anxiety, as determined by the EPDS-A, were significantly more 
likely to be suicidal based on both question ten on the EPDS and by verbal report to their 
clinician. According to Sareen et al. (2005), presence of anxiety disorders was 
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significantly associated with suicidal ideation (aOR 2.32; 95% CI 1.31-4.11) and suicide 
attempts (aOR 3.64; 95% CI 1.70-7.83). 
Limitations 
 Our study has several limitations. One of the biggest limitations was the amount 
of gaps in the data. Ideally, we would have had data for all ninety-one women at all six 
time points, however, many women only completed two time points severely limiting the 
interpretation of our results. Secondly, there were two sites to this study: UNC and JHU 
with only two UNC participants. It is possible that different methods, environment, and 
care between the two sites skewed the results slightly.  
This study was also not originally designed or powered for the purpose of 
studying anxiety and its relation to suicidality. As a result, we did not administer scales 
specific for anxiety, such as the State-Trait Anxiety inventory or Beck Anxiety Inventory. 
We used the anxiety subscale of the EPDS to assess anxiety and a cut-off of six, which 
has been reported in the literature (Matthey, 2008). However, other cut-off scores have 
also been reported (Swalm et al., 2010; Schofield et al., 2014). Additionally, we relied on 
single-questions from different scales to assess suicidality. It has been suggested that 
question ten on the EPDS is really a measure of self-harm, rather than suicidality (Mauri 
et al., 2012). Using a more thorough specific suicidality assessment, such as the 
suicidality module in the M.I.N.I. might have yielded more accurate results.  
The population chosen for the study prevents generalizing the findings to the 
general population. The fact that we studied a mood disorder population limits the 
applicability of these data to the general perinatal population. Future studies can use a 
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larger group of participants and recruit from the general public, rather than a mood 
disorder population, which would not only allow for more generalizable results, but also 
for a larger subject pool and better data. In addition, a small sample size was used in this 
study. The study occurred mainly in Baltimore, Maryland and therefore, the data may not 
be generalizable to the US as a whole. Future studies could use a multi-center design to 
allow for a better representation of the entire US perinatal population. It is also important 
that all participants be recruited during early pregnancy and retained throughout 
pregnancy and into the postpartum period. Many studies on anxiety and suicidality during 
the perinatal period are conducted in other countries and there is a need for more research 
here in the US. While research from other countries is helpful, it is not directly 
comparable to the US population. There is also a need for more research using the new 
DSM-V, which was published in 2013. A major barrier to direct comparisons between 
many studies is the number of different scales that are used to measure depression, 
anxiety, suicidality, etc. There is a need for simplification and standardization of these 
measures to allow for more direct comparison between studies. Once more research is 
conducted on the prevalence, risk factors, and consequences of anxiety disorders during 
the perinatal period, the next step is to begin research methods of treating anxiety during 
the perinatal period.   
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CONCLUSION 
 In conclusion, we found that significant symptoms of anxiety during the perinatal 
period are a risk factor for suicidality during the perinatal period in women with histories 
of mood disorders. Specifically, significant anxiety symptoms were a risk factor for 
suicidality during the third trimester and one month postpartum. In our study, we found 
symptoms of anxiety to be prevalent during the perinatal period. In addition, suicidal 
ideation or thoughts of self-harm were relatively common during this period. While this 
study adds to the growing research on psychiatric issues, specifically anxiety disorders, 
during the perinatal period, more research is needed. The scope of research and in clinical 
practice needs to be broadened to include anxiety in addition to mood disorders. 
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